MYOGEN INC. - mit besten Aussichten - 500 Beiträge pro Seite

[bioperformer]

Werde in den nächsten Tagen mal was über das o.g. Unternehmen reinstellen. Im Vorab mal der zugegebenermaßen im Moment nicht gerade einladende Chart, der aber mit an Sicherheit grenzender Wahrscheinlichkeit bald deutlich in die richtige Richtung tendieren wird.

[bioperformer]

Wie bereits eingangs erwähnt mal ein paar Infos zum Unternehmen, bzw. deren Ausrichtung.

Myogen - www.myogen.com - wurde 1986 gegründet, Forschungsschwerpunkte sind Bluthochdruck, Herzgefäßerkrankungen sowie Herzinfarkt.
Ein Milliardenmarkt also, wenn man bedenkt daß Schätzungen zufolge die Anzahl der Erkrankungen allein in US um ca 1/2 Mio. Patienten pro Jahr ansteigt.
Das wiederum hat zur Folge, daß ein Anstieg des Gesamtmarktvolumens auf dem CHF-Therapeutiksektor von aktuell ca. 14 Mrd. auf mehr als 22 Mrd.US-$ prognostiziert wird. Konservativ geschätzt!!

Ein Blick auf die Pipeline zeigt, daß Myogen bereits ein Produkt vertreibt - wenn auch vorerst nur in Europa - aber immerhin damit bereits erste Einnahmen generiert, was ja durchaus nicht die Regel ist.
Drei weitere Produktanwärter in teilweise späten klinischen Phasen stehen da ebenfalls noch im Raum, somit kann es hier neben dem durchaus vorhandenen Risiko auf schlechte Forschungsdaten aber auch bei positivem Newsflow mal sehr schnell nach oben gehen.
Kooperationsvereinbarungen mit einem Big-Player (Novartis)sind ebenfalls bereits vorhanden, was sich eigentlich nur positiv auswirken kann.

Myogen ist bei einem Kurs von 8,5 US$ mit ca. 223 Mio. bewertet, verfügt nach Abzug aller Verbindlichkeiten über ca. 90 Mio US$ oder 3,40 US$ per Share.

Das Unternehmen ist seit Herbst letzten Jahres gelistet.
Eine relativ hohe Aktienanzahl befindet sich in Händen von Institutionellen ( 45,05% ), was nicht gerade der üblichen Quote bei IPO`s entpricht.

[bioperformer]

na also, erstes STRONG-BUY Rating vom StockPickReport eingetrudelt!


Rating: STRONG BUY
Price: $8.26
Sector: DRUGS - Drug Manufacturers - Other
Region: Colorado
Company Information:
Myogen Inc
7575 West 103rd Avenue Suite 102
Westminster, Colorado 80021


StockPickReport.Com research suggests MYOG`s price will move significantly higher than the "open price" the day this rating was initiated. This analysis is based on short-term stochastic and "relative strength" indicators. Both stochastic and "relative strength" indicators point to a move up. Investors, traders, and other market participants may find this a good opportunity to buy MYOG, "buy calls", or "sell puts". This may also be an opportunity to raise targets and stop/losses to allow for potential gains. Trading volume seems to be falling and MYOG`s closing price moved up during the week before this rating was initiated.


Myogen, Inc., a development stage company, operates as a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. The company markets one product in Europe, Perfan I.V., which is used in a hospital setting to treat patients with acute decompensated heart failure and to wean patients from cardiopulmonary bypass following open-heart surgery. It sells Perfan I.V. through local distributors in Belgium, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, and the United Kingdom. Besides, it had, as of June 30, 2003, three product candidates in late-stage clinical development: enoximone capsules for the treatment of chronic heart failure; ambrisentan for the treatment of pulmonary arterial hypertension; and darusentan for the treatment of uncontrolled hypertension. Enoximone, a type-III selective phosphodiesterase inhibitor, is a positive inotropic agent that increases the force of contraction of the heart. Ambrisentan, an ETA selective endothelin receptor antagonist, is a potent inhibitor of endothelin-induced vasoconstriction. Darusentan, an ETA selective endothelin receptor antagonist, is a potent inhibitor of endothelin-induced vasoconstriction. In addition, the company conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders. Its significant competitors comprise Actelion, Ltd.; Encysive Pharmaceuticals, Inc.; GlaxoSmithKline plc; Orion Pharma; United Therapeutics Corp.; and Vasogen, Inc.

[bioperformer]

Myogen (MYOG) Initiates Phase II Clinical Trial Of Darusentan For Resistant Systolic Hypertension


DENVER, July 15 /PRNewswire-FirstCall/ -- Myogen, Inc. , a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced the initiation of a Phase IIb clinical trial to evaluate the safety and efficacy of darusentan in patients with resistant systolic hypertension.

"Recent clinical studies suggest that, despite the availability and use of multiple drugs, a considerable number of patients with hypertension remain at risk for progressive cardiovascular and renal complications due primarily to inadequately controlled blood pressure," said J. William Freytag, Ph.D., President and Chief Executive Officer of Myogen. "The results of these studies lead us to believe that there is a need for new antihypertensive drugs, with unique mechanisms of action compared to existing approved therapies, that can act additively with currently available antihypertensive drugs to lower blood pressure in patients with resistant hypertension. We believe the initiation of this clinical trial represents a significant step in both the development of darusentan as a potential add-on therapy for patients with resistant hypertension and in expanding Myogen`s product pipeline to a third compound for a third indication."

The primary objective of the Phase IIb randomized, double-blind, placebo- controlled trial is to determine if darusentan is effective in reducing systolic blood pressure in patients with resistant systolic hypertension. Resistant hypertension is defined by The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure sponsored by the National Institutes of Health (JNC7) as the failure to achieve goal blood pressure in patients who are adhering to full doses of an appropriate three-drug regimen that includes a diuretic. Approximately 105 patients will be randomized to darusentan or placebo at approximately 30 investigative sites. Patients will undergo forced titration every two weeks through 10, 50, 100 and 150 mg of darusentan or placebo until the target dose of 300 mg once a day is achieved. The treatment period for the study is 10 weeks.

Darusentan is a type-A selective endothelin receptor antagonist and potent inhibitor of endothelin-induced vasoconstriction. Endothelin is a small peptide hormone that is believed to play a critical role in the control of blood flow and cell growth. Elevated endothelin blood levels are associated with several cardiovascular disease conditions, including pulmonary arterial hypertension, chronic kidney disease, hypertension, chronic heart failure, stroke and reclosure of coronary arteries after balloon angioplasty or stent implantation. Therefore, many scientists believe that agents that block the detrimental effects of endothelin will provide significant benefits in the treatment of these conditions. Darusentan is selective for the ET(A) receptor versus the ET(B) receptor and demonstrates a half-life that may be suitable for once a day dosing.

In 2000, the original sponsor of darusentan evaluated the safety and efficacy of darusentan in 392 patients with moderate essential hypertension in a Phase II/III randomized, double-blind, placebo-controlled, dose-ranging trial. The primary endpoint of the trial was change in sitting diastolic blood pressure after six weeks of treatment.

The results of this study demonstrated that darusentan produced statistically significant and clinically meaningful reductions in diastolic and systolic blood pressures in a dose-dependent manner. The mean placebo- corrected change from baseline in systolic blood pressure was -6.0 mmHg on 10 mg, -7.3 mmHg on 30 mg and -11.3 mmHg on 100 mg darusentan after six weeks of treatment. Significant reductions in diastolic blood pressure were also observed (-3.7, -4.9 and -8.3 mmHg, for the three dose groups, respectively). Heart rate remained unchanged in all groups. Headache was the most commonly reported adverse event, with no relevant difference among placebo and active treatment groups. Flushing and peripheral edema were seen in a dose-dependent fashion in the darusentan treatment groups. There were no treatment-related elevations in liver function tests in the study. This study was conducted with a different patient population and protocol than is being studied in the Company`s Phase IIb clinical trial and there can be no assurances that Myogen will see the same results in its Phase II study as those reported in this study.

About Hypertension

Hypertension affects approximately 50 million individuals in the United States and approximately one billion worldwide. Despite the availability and use of several classes of drugs (diuretics, ACE inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, alpha receptor agents and vasodilators) to treat hypertension, many of these patients do not achieve goal blood pressures within the recommended range, a condition described as "resistant hypertension". Many of these patients have diabetes, chronic kidney disease or both. The relationship between blood pressure and cardiovascular events is continuous, consistent and independent of other risk factors. The likelihood of patients developing cardiovascular and renal complications rises as blood pressure increases.

About Myogen

Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. Myogen currently markets one product in Europe for the treatment of acute decompensated heart failure and has three product candidates in late-stage clinical development: enoximone capsules for the treatment of chronic heart failure, ambrisentan for the treatment of pulmonary arterial hypertension and darusentan for the treatment of resistant hypertension. The Company, in collaboration with Novartis, also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders. Please visit Myogen`s website at http://www.myogen.com/." target="_blank" rel="nofollow ugc noopener">http://www.myogen.com/.

Safe Harbor Statement

This press release contains forward-looking statements that involve significant risks and uncertainties, including those discussed in this release and others that can be found in the "Risk Factors" section of Myogen`s Form 10-K for the year ended December 31, 2003 and in Myogen`s periodic reports on Form 10-Q and Form 8-K. Myogen is providing this information as of the date of this release and does not undertake any obligation to update any forward- looking statements contained in this document as a result of new information, future events or otherwise.

The Company cautions investors not to place undue reliance on the forward- looking statements contained in this press release. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected. The Company`s results may be affected by its effectiveness at managing its financial resources, its ability to successfully develop and market current and new products, difficulties or delays in its clinical trials, difficulties or delays in manufacturing its products, and regulatory developments involving current and future products. Delays in clinical trials, whether caused by adverse events, patient enrollment rates, regulatory issues or other factors, could adversely affect the Company`s financial position and prospects. Results from earlier clinical trials are not necessarily predictive of future clinical trial results. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue one or more of its drug development or discovery research programs. Myogen is at an early stage of development and may not ever have any products that generate significant revenue.

Myogen
CONTACT: Derek K. Cole, Director, Investor Relations, [phone],[e-mail], or Joseph L. Turner, Chief Financial Officer,[phone], [e-mail], both of Myogen

Web site: http://www.myogen.com/

[derschweizer]

@bioperformer

Hallo,

ich habe mir Myogen angeschaut. Die Pipeline sieht wirklich interessant aus und ist weit fortgeschritten. Die vorklinische Forschung umfasst Wirkstoffe mit Block Buster qualitäten. Charttechnisch angeschlagen wie mein gesamtes Depot also nicht neues. Der Kurs steht Aktuell bei 7,20 US$, knapp 190 Mio.US$ Marketcap. Chancenreich ist die Aktie auf jeden Fall.

Rein in die Watchliste, danke für die Info`s

derschweizer

[bioperformer]

@derschweizer


..bitte, gern geschehen.

Am Rande noch ein Hinweis auf ein weiteres, äußerst chancenreiches Unternehmen, sozusagen als Tipp sich den nächsten Regentag etwas aufzuhellen.

ACUSPHERE, WKN 727232


Gruß Bio

[bioperformer]

Myogen to Announce 2004 Second Quarter Results on August 5, 2004
Tuesday July 27, 4:03 pm ET


DENVER, July 27 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG - News), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disease, today announced that it will report 2004 second quarter results on Thursday, August 5, 2004, before the U.S. financial markets open.
ADVERTISEMENT


J. William Freytag, President and CEO, and other members of Myogen`s senior management will provide a company update and discuss results via webcast and conference call on Thursday, August 5, 2004 at 4:15 pm Eastern. To access the live webcast, please log on to the company`s website at www.myogen.com and go to the Investor Relations section. Alternatively, callers may participate in the conference call by dialing 800-366-7417 (domestic) or 303-262-2075 (international). Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Friday, August 20, 2004. Callers can access the replay by dialing 800-405-2236 (domestic) or 303-590-3000 (international). The passcode is 11004085#.

[bioperformer]

U.S. FDA Grants Orphan Drug Designation for Ambrisentan
Tuesday August 3, 6:30 am ET


DENVER, Aug. 3 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG - News), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to ambrisentan for the treatment of pulmonary arterial hypertension (PAH). Ambrisentan is currently being evaluated for PAH in two pivotal Phase III trials, ARIES-1 & -2.
"The FDA`s grant of orphan drug designation to ambrisentan for PAH strengthens our development program by offering regulatory, clinical development and commercial benefits," said J. William Freytag, Ph.D., President and Chief Executive Officer of Myogen.

The U.S. Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders. Under the Orphan Drug Act, upon marketing authorization, the FDA does not accept or approve other applications to market the same medicinal product for the same therapeutic indication for a seven-year period. In addition to potential market exclusivity, orphan drug designation provides protocol assistance, advice on the conduct of clinical trials, tax credits for clinical research expenses, grant funding for research of rare disease treatments and waiver of the Prescription Drug User Fee Act (PDUFA) filing fee.

About Ambrisentan

Ambrisentan is a type-A selective endothelin receptor antagonist and potent inhibitor of endothelin-induced vasoconstriction. Endothelin is a small peptide hormone that is believed to play a critical role in the control of blood flow and cell growth. Elevated endothelin blood levels are associated with several cardiovascular disease conditions, including pulmonary arterial hypertension, chronic kidney disease, hypertension, chronic heart failure, stroke and reclosure of coronary arteries after balloon angioplasty or stent implantation. Therefore, many scientists believe that agents that block the detrimental effects of endothelin will provide significant benefits in the treatment of these conditions. Ambrisentan is selective for the ET(A) receptor versus the ET(B) receptor and demonstrates a half-life that may be suitable for once a day dosing.

About Myogen

Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. Myogen currently markets one product in Europe for the treatment of acute decompensated heart failure and has three product candidates in late-stage clinical development: enoximone capsules for the treatment of chronic heart failure, ambrisentan for the treatment of pulmonary arterial hypertension and darusentan for the treatment of resistant hypertension. The Company, in conjunction with Novartis, also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders. Please visit Myogen`s website at www.myogen.com.

Safe Harbor Statement

This press release contains forward-looking statements that involve significant risks and uncertainties, including those discussed in this release and others that can be found in the "Risk Factors" section of Myogen`s Annual Report on Form 10-K filed on March 1, 2004. Myogen is providing this information as of the date of this release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected. The Company`s results may be affected by its effectiveness at managing its financial resources, its ability to successfully develop and market current and new products, difficulties or delays in its clinical trials, difficulties or delays in manufacturing its products, and regulatory developments involving current and future products. Delays in clinical trials, whether caused by adverse events, patient enrollment rates, regulatory issues or other factors, could adversely affect the Company`s financial position and prospects. Results from earlier clinical trials are not necessarily predictive of future clinical results. Receiving orphan drug designation does not increase the likelihood of eventual regulatory approval for a product candidate. Ambrisentan is not registered for sale for any indication in the United States or abroad. If ambrisentan does not meet safety and efficacy endpoints in clinical evaluation, it will not receive regulatory approval. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue one or more of its drug development or discovery research programs. Myogen is at an early stage of development and may not ever have any products that generate significant revenue.




--------------------------------------------------------------------------------
Source: Myogen, Inc.

[bioperformer]

Orderbook INET 6,84 zu 10,99 ???


Nach dem gestern erhaltenen Orphan Drug Status für Ambrisentan und den morgen anstehenden Quartalszahlen vorbörslich o.g. Spanne.

Fehler, Tatsache oder Anderweitiges??

[bioperformer]

Myogen Reports 2004 Second Quarter Results
Thursday August 5, 6:30 am ET


DENVER, Aug. 5 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG - News), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today reported 2004 second quarter results. As of June 30, 2004, the Company had cash, cash equivalents and investments of $85.8 million. Net loss attributable to common stockholders for the three months ended June 30, 2004 was $13.2 million, or $0.50 per share, compared with $15.9 million, or $15.47 per share, during the same period in 2003. Net loss attributable to common stockholders for the six months ended June 30, 2004 was $29.2 million, or $1.10 per share, compared with $27.2 million, or $26.41 per share, during the same period in 2003.
"Myogen continues to execute its development plan for our three product candidates," said J. William Freytag, President and Chief Executive Officer of Myogen. "We have completed patient enrollment in the two Phase III registration trials for enoximone to treat chronic heart failure, initiated the Phase IIb study of darusentan for the treatment of resistant hypertension and our Phase III registration trials for ambrisentan to treat pulmonary arterial hypertension are on-going. In July, we hosted our first investor/analyst day which attracted over 40 portfolio managers and equity research analysts with additional participants viewing the live webcast. We are looking forward to the second half of the year and furthering the development of enoximone, ambrisentan, darusentan and our discovery research program."

Product Portfolio Update

Enoximone:
* ESSENTIAL I & II, the Company`s two pivotal Phase III trials of
enoximone capsules in patients with chronic heart failure, continue to
progress in line with expectations. In May, the Company announced the
completion of enrollment of 1,800 patients in ESSENTIAL I & II. The
trials will continue until there have been a total of 956 primary
endpoint events (cardiovascular hospitalization or all-cause
mortality). The Company expects that the specified number of events
will have occurred by the end of this year.

* EMOTE, a non-pivotal Phase III trial of enoximone capsules in 201
patients in advanced stages of chronic heart failure who are dependent
on intravenous (i.v.) inotrope therapy, was completed in February.
Preliminary results were reported in March 2004. Additional results
will be presented at the 8th Annual Scientific Meeting of the Heart
Failure Society of America on September 15, 2004 in Toronto, Canada.

* EMPOWER, an additional non-pivotal Phase III trial designed to provide
potential marketing support, began enrollment in September 2003.
Trial enrollment continues to progress, but remains slower than
projected. The Company continues to monitor the viability of the
trial.


The Company believes that if the ESSENTIAL trials are successful, the results will be adequate to support regulatory submission for enoximone capsules in the United States as well as in certain international markets. Although the Company does not believe that EMOTE or EMPOWER will be required for regulatory approval, it believes these studies may assist in regulatory and post-approval marketing efforts.

Ambrisentan: In January, Myogen announced the initiation of patient enrollment in ARIES-1 & -2, two pivotal Phase III trials of ambrisentan in pulmonary arterial hypertension (PAH). The Company`s goal is to complete enrollment in the two trials by the end of the first half of 2005. This timing is increasingly uncertain due to a number of factors, including the declining numbers of patients with PAH who are treatment naive seen at clinical trial sites as well as competing on-going trials. The Company is committing additional resources in an effort to accelerate patient enrollment in order to increase the likelihood of completing enrollment in the expected time frame. Upon completion of treatment in the ARIES trials, patients are eligible to enroll in a long-term extension study. The United States Food and Drug Administration (FDA) has granted orphan drug designation to ambrisentan for the treatment of PAH.

Darusentan: In July, the Company announced the initiation of a Phase IIb clinical trial to evaluate the safety and efficacy of darusentan in patients with resistant systolic hypertension. The primary objective of the randomized, double-blind, placebo-controlled trial is to determine if darusentan is effective in reducing systolic blood pressure in patients with resistant systolic hypertension. Resistant hypertension is defined by The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure sponsored by the National Institutes of Health (JNC7) as the failure to achieve goal blood pressure in patients who are adhering to full doses of an appropriate three-drug regimen that includes a diuretic. Approximately 105 patients will be randomized to darusentan or placebo at approximately 30 investigative sites. Patients will undergo forced titration every two weeks through 10, 50, 100 and 150 mg of darusentan or placebo until the target dose of 300 mg once a day is achieved. The treatment period for the study is 10 weeks.

2004 Second Quarter Financial Highlights

Sales of Perfan I.V. for the three months ended June 30, 2004 were $900,000 versus $708,000 for the same period in 2003. The increase in sales from the prior year period was the result of a more favorable exchange rate and a 17% increase in the number of units sold. The cost of Perfan I.V. sold as a percentage of sales was 31% and 32% for the three months ended June 30, 2004 and 2003, respectively. For the three months ended June 30, 2004, research and development contracts revenue from our research agreement with Novartis was $1.7 million.

Research and development expenses, excluding stock-based compensation expenses, increased 11% to $12.5 million from $11.2 million for the three months ended June 30, 2004 and 2003, respectively. The increase in expenses for the period was primarily due to costs associated with increased patient enrollment in the ESSENTIAL and ARIES trials and costs for preparations to initiate the darusentan Phase IIb trial.

Selling, general and administrative expenses, excluding stock-based compensation expenses, increased 111% to $2.0 million from $970,000 for the three months ended June 30, 2004 and 2003, respectively. The increase was primarily due to an increase in insurance and professional service costs related to becoming a public company and an increase in staffing and related recruiting costs.

2004 Milestones
* Myogen milestones for 2004 include:
* Initiation of ARIES-1 & -2 (ambrisentan pivotal Phase III studies),
which the Company announced in January;
* Completion of EMOTE (enoximone non-pivotal Phase III study), the
preliminary results of which the Company reported in March;
* Initiation of a Phase IIb trial of darusentan in resistant
hypertension, which the Company announced in July; and
* Completion of patient enrollment, which the Company announced in May,
and drug treatment in ESSENTIAL I & II (enoximone pivotal Phase III
studies) by the end of the year.


2004 Financial Guidance

Financial projections entail a high level of uncertainty due, among many factors, to the variability involved in predicting clinical trial enrollment rates, availability, terms and timing of additional financing transactions and the potential for Myogen to enter into additional licensing or strategic collaborations. The Company plans on updating financial guidance for 2004 when it releases results for each quarter or upon the announcement of material corporate events.

Based upon results through the second quarter, the Company is updating its financial guidance. For the year ending December 31, 2004, the Company presently anticipates:

* Total product sales of $2.8 million to $3.3 million, an upward
revision from previous guidance of $2.5 million to $3.0 million;
* Total operating expenses, excluding stock-based compensation expenses,
of $62 million to $75 million, a downward revision from previous
guidance of $66 million to $78 million; and,
* Basic net loss per share between $2.30 and $2.76, a reduction in
anticipated net loss compared to previous guidance of between
$2.46 and $2.92.


In addition, based on current spending projections, the Company believes its cash, cash equivalents and investments are sufficient to fund operations through the middle of next year.

Conference Call

J. William Freytag, President and CEO, and other members of Myogen`s senior management will provide a company update and discuss results via webcast and conference call on Thursday, August 5, 2004 at 4:15 pm Eastern. To access the live webcast, please log on to the company`s website at www.myogen.com and go to the Investor Relations section. Alternatively, callers may participate in the conference call by dialing 800-366-7417 (domestic) or 303-262-2075 (international). Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Friday, August 20, 2004. Callers can access the replay by dialing 800-405-2236 (domestic) or 303-590-3000 (international). The passcode is 11004085#.

About Myogen

Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. Myogen currently markets one product in Europe for the treatment of acute decompensated heart failure and has three product candidates in late-stage clinical development: enoximone capsules for the treatment of chronic heart failure, ambrisentan for the treatment of pulmonary arterial hypertension and darusentan for the treatment of resistant hypertension. The Company also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders. Please visit Myogen`s website at www.myogen.com.

Safe Harbor Statement

This press release contains forward-looking statements that involve significant risks and uncertainties, including those discussed in this release and others that can be found in the "Risk Factors" section of Myogen`s Annual Report on Form 10-K for the year ended December 31, 2003 and in Myogen`s periodic reports on Form 10-Q and Form 8-K. Myogen is providing this information as of the date of this release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

The Company cautions investors not to place undue reliance on the forward- looking statements contained in this press release. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected. The Company`s results may be affected by its effectiveness at managing its financial resources, its ability to successfully develop and market current and new products, difficulties or delays in its clinical trials, difficulties or delays in manufacturing its products, and regulatory developments involving current and future products. Delays in clinical trials, whether caused by adverse events, patient enrollment rates, regulatory issues or other factors, could adversely affect the Company`s financial position and prospects. Results from earlier clinical trials are not necessarily predictive of future clinical results. Preliminary results may not be confirmed upon full analysis of the detailed results of a trial. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue one or more of its drug development or discovery research programs. Myogen is at an early stage of development and may not ever have any products that generate significant revenue.

MYOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(Unaudited)

June 30, December 31,
2004 2003

ASSETS
Current assets:
Cash and cash equivalents $13,931,887 $44,337,721
Short-term investments 68,388,299 69,914,627
Accrued interest receivable 454,326 607,393
Trade accounts receivable 1,277,245 1,274,861
Research and development contract
amounts due within one year 2,247,000 1,625,000
Inventories 679,626 724,282
Prepaid expenses and other current assets 1,328,018 1,434,174
Total current assets 88,306,401 119,918,058

Long-term investments 3,490,523 --
Property and equipment, net 1,999,208 1,304,028
Other assets 42,798 51,238

Total assets $93,838,930 $121,273,324

LIABILITIES AND STOCKHOLDERS` EQUITY

Current liabilities:
Accounts payable $9,034,599 $7,594,935
Accrued liabilities 972,764 1,350,114
Current portion of deferred revenue 1,666,667 1,666,667
Current portion of capital lease
obligations 41,452 37,015
Current portion of notes payable,
net of discount 1,728,295 1,639,246
Total current liabilities 13,443,777 12,287,977

Deferred revenue, net of current portion 2,114,695 2,948,029
Capital lease obligations, net of
current portion 105,616 121,617
Notes payable, net of current portion
and discount 1,106,952 1,993,906

Stockholders` equity:
Preferred Stock, $0.001 par value;
5,000,000 shares authorized at
June 30, 2004 and December 31, 2003,
no shares issued or outstanding -- --
Common stock, $0.001 par value;
100,000,000 shares authorized and
26,520,586 and 26,457,927 shares issued
and outstanding as of June 30, 2004 and
December 31, 2003, respectively 26,521 26,458
Additional paid-in-capital 228,834,480 229,080,380
Deferred stock-based compensation (4,084,705) (6,730,195)
Accumulated other comprehensive income (34,583) 22,185
Deficit accumulated during the
development stage (147,673,823) (118,477,033)
Total stockholders` equity 77,067,890 103,921,795

Total liabilities and
stockholders` equity $93,838,930 $121,273,324


MYOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

For the Three Months Ended For the Six Months Ended
June 30, June 30,
2004 2003 2004 2003

Revenues:
Product sales $899,831 $708,425 $1,751,478 $1,364,810
Research and
development
contracts 1,663,667 -- 3,003,295 --
2,563,498 708,425 4,754,773 1,364,810

Costs and expenses:
Cost of product
sold 277,574 227,049 548,704 433,946
Research and
development
(excluding
stock-based
compensation
expense of
$535,183,
$304,040,
$1,151,131 and
$742,394,
respectively) 12,461,672 11,218,657 27,086,108 17,569,894
Selling,
general and
administrative
(excluding
stock-based
compensation
expense of
$586,839,
$189,196,
$1,182,745 and
$522,492,
respectively) 2,046,850 970,048 4,282,128 1,901,571
Stock-based
compensation
expense 1,122,022 493,236 2,333,876 1,264,886
15,908,118 12,908,990 34,250,816 21,170,297

Loss from
operations (13,344,620) (12,200,565) (29,496,043) (19,805,487)
Interest income
(expense), net 136,762 (35,550) 308,640 (8,254)

Loss before
income taxes (13,207,858) (12,236,115) (29,187,403) (19,813,741)
Income taxes 2,511 8,320 9,387 10,635

Net loss (13,210,369) (12,244,435) (29,196,790) (19,824,376)
Accretion of
mandatorily
redeemable
convertible
preferred stock -- (3,670,184) -- (7,340,369)

Net loss
attributable
to common
stockholders $(13,210,369) $(15,914,619) $(29,196,790) $(27,164,745)
Basic and
diluted net
loss per
common share $(0.50) $(15.47) $(1.10) $(26.41)
Weighted
average
common shares
outstanding 26,490,954 1,028,736 26,476,058 1,028,517




--------------------------------------------------------------------------------
Source: Myogen, Inc.

[bioperformer]

mal Hand aufs Herz und ganz ehrlich: wieviele Unternehmen mit derartigem Chance/Risikoverhältnis gibt es da wohl zur Zeit?

Mit zwei potenziellen Blockbuster-Kandidaten, einem bereits eingeführtem Produkt welches bereits Einkünfte erzielt, sowie einer 50%-Absicherung des aktuellen Kurses durch eigene Mittel sehe ich außer der momentanen Übertreibung nach unten wenig Gefahrenpotenzial.

Auf Basis des Vorjahresquartals konnte der Umsatz ca. vervierfacht werden, doch ist dieser sowieso seit sechs Quartalen permanent steigend.

Ausgaben wie erwartet unwesentlich höher als im Vergleichszeitraum, jedoch haben sich die Verluste auch deutlich verringert.

Insgesamt gesehen dürften diese Quartalszahlen wohl deutlich besser ausgefallen sein als allgemein erwartet.
Daran dürfte auch die sich aktuell zeigende "Kurspflege nach unten" nichts ändern. Scheinbar muß hier noch für die Großen vorgearbeitet werden...

Egal, wie auch immer, so kann man ich mir noch günstig ein paar Stücke für die lange Bank sichern.


Grüße auch an den urlaubenden schweizer bio

[bioperformer]

Myogen Seen With Slimmer 2004 Loss
08.05.04, 3:47 PM ET



Credit Suisse First Boston narrowed the estimated 2004 loss for Myogen (nasdaq: MYOG - news - people ) after the biopharmaceutical company announced a smaller-than-expected second-quarter loss. Myogen reported a quarterly loss of 50 cents compared with CSFB`s estimated loss of 66 cents. The research firm, which rates the company at "neutral" with a target price of $17, narrowed the estimated loss for 2004 to $2.40 per share from $2.55. CSFB added that the company expects to complete enrollment in its Phase III trials for Myogen`s ambrisentan drug, used for the treatment of pulmonary arterial hypertension, by the first half of 2005.



Wenn dann genügend Shares zum Schleuderpreis in die Depots der größeren Adressen geprügelt wurden, werden die ersten Kaufempfehlungen nicht lange auf sich warten lassen.

[bioperformer]

Myogen, Inc.
Event Detail




Event: EMOTE Results to be Presented at the 8th Annual Scientific Meeting of the Heart Failure Society of America
Start Date: Sep 15, 2004
Location: Metro Toronto Convention Centre (North Building) in Toronto, Ontario, Canada.

[bioperformer]

Anteil Institutioneller Anleger deutlich steigend


Aktuell bereits ca. 51% der verfügbaren Shares in den Depots von Institutionellen gelandet, oder besser gesagt hineingeprügelt.

Diese Quote wird im Hinblick auf die noch im Herbst anstehenden P3-Ergebnisse aber noch deutlich ansteigen, da im Erfolgsfall mit signifikanten Kurszuwächsen zu rechnen ist.

[bioperformer]

Enoximone Data to Be Presented at HFSA Annual Scientific Meeting
Wednesday September 8, 6:30 am ET


DENVER, Sept. 8 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG - News), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced that Arthur M. Feldman, M.D., Ph.D., will present detailed results of EMOTE, the non-pivotal Phase III study of enoximone capsules in chronic heart failure ("CHF"), at the 8th Annual Scientific Meeting of the Heart Failure Society of America ("HFSA"). Myogen previously disclosed preliminary results of the study in March 2004. Dr. Feldman`s abstract has been selected for presentation at the "Late Breaking Clinical Trials" session, Wednesday, September 15, 2004, at 8:30 a.m. (Eastern). Dr. Feldman is Magee Professor and Chair of the Department of Medicine at Jefferson Medical College of Thomas Jefferson University and the principal investigator for EMOTE.
ADVERTISEMENT


The 8th Annual Scientific Meeting of the HFSA will be held Sunday, September 12, through Wednesday, September 15, 2004 at the Metro Toronto Convention Centre (North Building) in Toronto, Ontario, Canada. Additional conference information is available at http://www.hfsa.org/annual_meeting.asp.

EMOTE is a non-pivotal Phase III trial of enoximone capsules in 201 patients in the most advanced stage of CHF who are dependent on intravenous (i.v.) inotrope therapy. The study was designed to evaluate the effectiveness of enoximone capsules to wean patients off of i.v. inotrope therapy.

ESSENTIAL I & II, the Company`s two pivotal Phase III trials of enoximone capsules in patients with CHF, completed enrollment of over 1,800 patients in May 2004. The trials will continue until there have been a total of 956 primary endpoint events (cardiovascular hospitalization or all-cause mortality). The Company expects that the specified number of events will have occurred by the end of this year.

About Myogen

Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. Myogen currently markets one product in Europe for the treatment of acute decompensated heart failure and has three product candidates in late-stage clinical development: enoximone capsules for the treatment of chronic heart failure, ambrisentan for the treatment of pulmonary arterial hypertension and darusentan for the treatment of resistant systolic hypertension. The Company, in collaboration with Novartis, also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders. Please visit our website at www.myogen.com.

Safe Harbor Statement

This press release contains forward-looking statements that involve significant risks and uncertainties, including those discussed in this release and others that can be found in the "Risk Factors" section of Myogen`s Annual Report on Form 10-K filed on March 1, 2004. Myogen is providing this information as of the date of this release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

The Company cautions investors not to place undue reliance on the forward- looking statements contained in this press release. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected. The Company`s results may be affected by its effectiveness at managing its financial resources, its ability to successfully develop and market current and new products, difficulties or delays in its clinical trials, difficulties or delays in manufacturing its products, and regulatory developments involving current and future products. Delays in clinical trials, whether caused by adverse events, patient enrollment rates, regulatory issues or other factors, could adversely affect the Company`s financial position and prospects. Results from earlier clinical trials are not necessarily predictive of future clinical results. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue one or more of its drug development or discovery research programs. Myogen is at an early stage of development and may not ever have any products that generate significant revenue.




--------------------------------------------------------------------------------
Source: Myogen, Inc.

[bioperformer]

Im Hinblick auf den 15.09.04 wird es langsam eng für die Shorties,.

(Days to cover)

Aug. 13,2004 / 882.614 / 82.646 / ( 10.68 )
Jul. 15,2004 / 992.956 / 164.846 / ( 6.02 )


.... wenigstens habt ihr mir nochmals gute Einstiegskurse zum Nachlegen verschafft...

Fazit: Montag bricht die Kaufwut vollends aus.

[therman]

Hi bioperformer,

vielen Dank für die Infos.

Charttechnisch ist MYOG aus einem ausgedehnten
Bullkeil ausgebrochen.

Ich denke ich werde noch dazukaufen.

therman

[bioperformer]

Hallo therman, gerne geschehen.


Nach längerer Durststrecke hat der Kurs von MYOG denn doch mal zum Spurt nach Norden angesetzt. Für das im Moment noch fehlende deftige Volumen könnten schnell positive News bezüglich der P3-Tests sorgen.

Einhergehend mit genannten Spekulationen - angeblich sei die Mortalitätsrate signifikant gesunken - und ersten doch schon erstellten Rentabilitätsberechnungen wundert es mich nicht, wenn daraus Kursziele resultieren, die im Moment als zu hoch gegriffen erscheinen.

Bei genaueren Berechnungen jedoch stellt man sehr schnell fest, daß bei einem konservativ geschätzten Jahresumsatz in einer Range von 200-300 Mio. US$ sich nach derzeit aktuellem " Bewertungsmultiplikator 4" eine Marktkapitalisierung von rund einer Mrd. US$ errechnen läßt. Vorraussetzung dafür ist aber wie gesagt, ein Topergebnis bei P3.

Bei 26,5 Mio ausgegebener Shares läßt sich dann auch für die kleinen Rechenkünstler unschwer erkennen, auf welchem Preisniveau das Papier dann gehandelt wird.

[bioperformer]

InterWest Partners Closes Its Ninth Fund at $600 Million; Venture Firm Continues 25-Year Tradition of Life Sciences and Information Technology Investing



MENLO PARK, Calif.--(BUSINESS WIRE)--Sept. 13, 2004--InterWest Partners, a leading diversified venture capital firm, today announced the closing of InterWest Partners IX, a $600 million fund that will invest in early-stage life sciences and information technology companies. With the closing of this fund, InterWest Partners has cumulatively raised more than $2 billion. InterWest`s 11 partners, based in Menlo Park, California and Dallas, Texas, will continue to invest in companies throughout the United States.

InterWest`s diversified investment approach, deep domain expertise and superior track record resulted in a high level of interest from investors.

"We are grateful to have received substantial support from existing investors and considerable interest from prospective new investors. This validates our consistent strategy of early-stage, active investing in both life sciences and information technology," said Flip Gianos, General Partner at InterWest Partners. "Both sectors continue to contribute significant investment returns to our limited partners."

Kevin Delbridge, of HarbourVest Partners, LLC, added, "Over the years, InterWest has consistently demonstrated its ability to start and build successful companies in each sector. We are confident they will continue this success and will deploy InterWest IX towards innovative ideas and experienced, entrepreneurial teams."

Since its inception in 1979, InterWest has played a key role in the success of more than 200 companies, including ArthroCare, CIENA, Copper Mountain Networks, Corixa, Cor Therapeutics, Coulter Pharmaceutical, Crystal Semiconductor, Cyrix, Inspire Pharmaceuticals, Lightera, Silicon Graphics, SiTera, Spinal Dynamics, Stratacom, TheraSense, Ventritex and Xilinx. The firm`s most recent fund, InterWest VIII, a $750M fund, includes the sale of PlaceWare to Microsoft, the sale of Epicor Medical to St. Jude Medical, and initial public offerings from Corgentech (Nasdaq:CGTK) and Myogen (Nasdaq:MYOG).

Mark Lortz, former President and CEO of TheraSense, added, "InterWest invested in us in 1998 when it was hard to get a venture capitalist interested in the medical device business. Throughout the history of TheraSense, from our beginnings to our recent IPO to our subsequent purchase by Abbott Labs for $1.2 billion, InterWest`s guidance and seasoned judgment were critical to our success."

The firm plans to begin InterWest IX investments early next year and expects to invest the fund over the next three to three and a half years.

About InterWest Partners

InterWest Partners (www.interwest.com), founded in 1979, is a leading diversified venture capital firm focused on building long-term relationships with entrepreneurs and portfolio companies. With more than $2 billion of capital raised, including its new investment fund of $600 million, InterWest has 11 experienced partners in Menlo Park, California and Dallas, Texas, who bring together deep domain knowledge in life sciences and information technology.

InterWest Partners has consistently helped grow some of the most influential companies in information technology and life sciences. The firm`s investments in information technology include: CIENA (CIEN), Copper Mountain Networks (CMTN), Cystal Semiconductor (acquired by Cirrus Logic, CRUS), Cyrix (CYRX; acquired by National Semiconductor), Lightera (acquired by CIENA), PlaceWare (acquired by Microsoft, MSFT), SiTera (acquired by Vitesse, VTSS), Silicon Graphics (SGI), Stratacom (STRM; acquired by Cisco, CSCO) and Xilinx (XLNX).

The firm`s investments in life sciences include: ArthroCare (ARTC), Cor Therapeutics (CORR; acquired by Millennium Pharmaceuticals, MLNM), Corgentech (CGTK), Corixa (CRXA), Coulter Pharmaceutical (CLTR; acquired by Corixa Pharmaceuticals, CRXA), Cubist Pharmaceuticals (CBST), Epicor Medical (acquired by Saint Jude Medical, STJ) Inspire Pharmaceuticals (ISPH), Myogen (MYOG), Spinal Dynamics (acquired by Medtronic, MDT), TheraSense (THER; acquired by Abbott Labs, ABT) and Ventritex (VNTX; acquired by St. Jude Medical, STJ).


CONTACT: InterWest Partners
Binay Curtis, 415-383-7243
415-596-6678 (Cell)
[e-mail]

SOURCE: InterWest Partners

[bioperformer]

Myogen derzeit mit technisch besten Vorraussetzungen, die 10 US$-Marke in Anriff zu nehmen. Die Hürden bei 7, bzw. 8 US$ sollten bei den seit Tagen sofort bei Kursschwäche einsetzenden Kauforders in der nächsten Zeit überwunden werden können.
Danach dürfte der Weg zumindest aus charttechnischer Sicht bis gut 10 US$ frei sein.

[bioperformer]

Aktuelle Short-Rate Liste SEPTEMBER 04


MYOG - Myogen, Inc. - Common Stock
Month
Short
Change Average Daily
Share Volume Days to cover


September 2004..744,448....68,080...10,93
August 2004.........882,614.....82,646...10,68
July 2004...............992,956...164,846....6,02
June 2004..........1,269,196...174,870....7,26
May 2004...............931,278...151,158....6,16
April 2004..............758,200...510,011....1,49
March 2004...........389,982.....77,367....5,04
February 2004.......308,288....82,160....3,75
January 2004.........172,769....85,888....2,01
December 2003....124,278....59,132....2,10
November 2003....174,200..497,623....1,00
October 2003.............. 0 N/A......0 N/A

[derschweizer]

@bioperformer

Hi bio,

die hohe Short-Rate lastet im Augenblick auf vielen Bios.
Sehr viele Unternehmen haben Medikamente in der letzten Phase der Entwicklung, oder haben den Zulassungsantrag schon gestellt.
Die Shorties hoffen natürlich auf Ausfälle, sprich schlechte Ergebniss / verweigerung der Zulassung usw.
Das jüngstes Beispiel dürfte Maxim sein hier verdienen Sie sich eine goldene Nase.
Im Augenblick ist das Risiko für Anleger im Bio-Sektor enorm hoch.

Myogen wird hoffentlich seinen Weg machen.

grüße derschweizer

[bioperformer]

@derschweizer



gruetzi schweizer,


...möchte nochmals das von dir angeschnittene Thema mit dem hohen Anteil an leerverkauften Aktien bei einigen Biotechs aufgreifen.

Dazu fällt mir schlagartig eines der beispielhaftesten Scenarios im Rahmen meiner "Biotech-Erfahrungen" ein.

Die Aktie, um die es sich damals handelte hieß Amylin Pharmaceuticals. Leider habe ich diesbezüglich keine Aufzeichnungen mehr, glaube aber mich erinnern zu können daß der damals komplette Bestand an Aktien geshortet war.
Vorausgegangen waren dem negative Meldungen über laufende Versuche.

Zu dieser Zeit wurden die Amylin-Shares regelrecht hinterhergeworfen, auch keines der renommierten Häuser hätte sich da irgendwie wohlwollend geäußert.

Als jedoch die ersten positiven Forschungsergebnisse ans Tageslicht kamen, war es recht schnell vorbei mit der Ruhe.

Was darauf folgte entspricht wohl dem, was man als gnadenloses Shortcovering bezeichnet. 500% waren hier sogar noch für die Schläfer drin.

Daß es hier -wie bei manch anderen Bios auch- zu teils deftigen Kursausschlägen nach oben kommt dürfte also auch hochgradig vom Vorhandensein einer nicht zu kleinen Menge zu covernden Shares abhängig sein.

In diesem Sinne freuen wir uns also über die noch offenen Positionen.



Bis denne, Bio

[bioperformer]

Press Release Source: Myogen, Inc.


Myogen Announces $60 Million Private Financing
Monday September 27, 6:01 am ET


DENVER, Sept. 27 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG - News), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced that it has entered into definitive purchase agreements for a $60 million private placement of newly issued shares of common stock and the concurrent issuance of warrants for the purchase of additional shares of common stock to institutional and accredited investors. The financing is expected to close on September 29, 2004.
ADVERTISEMENT


The Company intends to use net proceeds from the financing to continue the development of enoximone, ambrisentan and darusentan and the Company`s research program, to prepare for the potential commercial launch of enoximone and ambrisentan and for working capital and general corporate purposes.

At closing, the Company will issue 9.2 million shares of common stock at a price of $6.525 per share, together with warrants to purchase up to 1.8 million additional shares of common stock at an exercise price of $7.80 per share. Investors in the offering included previous Myogen stockholders New Enterprise Associates, InterWest Partners, Perseus-Soros Biopharmaceutical Fund and Sequel Venture Partners, as well as several new investors. CIBC World Markets and Lazard Freres & Co. LLC acted as joint placement agents for the transaction.

"We are gratified by the support and confidence our new and existing investors have expressed in Myogen`s product pipeline, management and business strategy with this financing," said J. William Freytag, President and Chief Executive Officer of Myogen. "We look forward to continuing to execute on a strategy we believe will enhance the long-term growth of the company and value for our stockholders."

The shares of common stock sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from the registration requirements. The shares were offered and sold only to institutional and accredited investors. The Company has agreed to file a registration statement with the SEC covering resale of the common stock issued in the private placement.

This news release is not an offer to sell or the solicitation of an offer to buy the shares of common stock of the Company.

About Myogen

Myogen currently markets one product in Europe for the treatment of acute decompensated heart failure and has three product candidates in late-stage clinical development: enoximone capsules for the treatment of chronic heart failure, ambrisentan for the treatment of pulmonary arterial hypertension and darusentan for the treatment of resistant systolic hypertension. The Company, in collaboration with Novartis, also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders. Please visit our website at www.myogen.com.

Safe Harbor Statement

This press release contains forward-looking statements that involve significant risks and uncertainties, including those discussed in this release and others that can be found in the "Risk Factors" section of Myogen`s Annual Report on Form 10-K for the year ended December 31, 2003 and in Myogen`s periodic reports on Form 10-Q and Form 8-K. Myogen is providing this information as of the date of this release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue one or more of its drug development or discovery research programs. Myogen is at an early stage of development and may not ever have any products that generate significant revenue. The Company`s results may be affected by its effectiveness at managing its financial resources, its ability to successfully develop and market current and new products, difficulties or delays in its clinical trials, difficulties or delays in manufacturing its products, and regulatory developments involving current and future products. Delays in clinical trials, whether caused by adverse events, patient enrollment rates, regulatory issues or other factors, could adversely affect the Company`s financial position and prospects. Results from earlier clinical trials are not necessarily predictive of future clinical results.




--------------------------------------------------------------------------------
Source: Myogen, Inc.

[bioperformer]

Die heute veröffentlichte Ankündigung einer Kapitalerhöhung scheint vom Markt ziemlich positiv aufgenommen zu werden, wertet man den heutigen Kursverlauf (derzeit 6% im Plus) und den doch eher lustlosen allgemeinen Wochenstart als Vorzeichen.

Offensichtlich wird das weitere Einsteigen von Großinvestoren doch als gewisser Grad von Sicherheit( die werden wohl die besten Infos über derzeitige Forschungsfortschritte haben) interpretiert.




...soll uns recht sein...

[bioperformer]

Myogen Updates Clinical Development and Financial Guidance
Tuesday September 28, 7:32 am ET
Company to Present at UBS Global Life Sciences Conference on Tuesday, September 28, 2004


DENVER, Sept. 28 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG - News), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disease, today updated its clinical development and financial guidance.
ADVERTISEMENT


ESSENTIAL I & II, the pivotal Phase III trials evaluating enoximone capsules in patients with chronic heart failure, continue to progress in line with expectations. In May, the Company announced the completion of enrollment of 1,800 patients for the two trials, with patient treatment to continue until 956 patients have had a primary endpoint event (cardiovascular hospitalization or all-cause mortality). The Company expects that the common termination date for both trials will occur by the end of this year. At that time, the mean treatment period will exceed 18 months. The Company expects to report preliminary top-line results mid-year 2005.

In January 2004, Myogen announced the initiation of patient enrollment in ARIES 1 & 2, the pivotal Phase III trials evaluating ambrisentan in pulmonary arterial hypertension. The Company reiterates its goal of completing patient enrollment in the ARIES trials by the end of the first half of 2005. The Company announced in August 2004 that it was adding additional resources to aid enrollment in the trials. Early indications suggest that the Company`s initiatives to accelerate enrollment to meet this target are having a positive effect, although several additional months will be required to draw definitive conclusions on the degree of impact. In addition, the Company expects to report preliminary results of the trials approximately six months following the completion of patient enrollment.

In July 2004, the Company announced the initiation of patient enrollment in a Phase IIb clinical trial designed to evaluate the safety and efficacy of darusentan in patients with resistant systolic hypertension. Enrollment in the 105 patient trial is progressing in line with expectations. The Company currently expects the trial to be completed mid-year 2005.

On September 27, 2004, the Company announced that it has entered into definitive purchase agreements for a $60 million private placement of newly issued shares of common stock and the concurrent issuance of warrants for the purchase of additional shares of common stock to institutional and accredited investors. Based on current spending projections, the Company believes its cash, cash equivalents, investments and the net proceeds from this private financing will be sufficient to fund operations through the end of 2005.

The Company also announced that J. William Freytag, President and CEO, will present a corporate overview at the UBS Global Life Sciences Conference. The presentation will take place at 4:00 p.m. (Eastern) on Tuesday, September 28, 2004. There will be a live webcast of the presentation from the conference. The webcast will be accessible through a link posted on the investor relations section of the Myogen website at http://investor.myogen.com/. The webcast will be available for replay on Myogen`s website through October 15, 2004.

Myogen currently markets one product in Europe for the treatment of acute decompensated heart failure and has three product candidates in late-stage clinical development: enoximone capsules for the treatment of chronic heart failure, ambrisentan for the treatment of pulmonary arterial hypertension and darusentan for the treatment of resistant hypertension. The Company, in collaboration with Novartis, also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders. Please visit our website at www.myogen.com.

Safe Harbor Statement

This press release and the anticipated presentation contain forward-looking statements that involve significant risks and uncertainties, including those discussed in this release, those to be discussed in the presentation and others that can be found in the "Risk Factors" section of Myogen`s Form 10-K for the year ended December 31, 2003 and in Myogen`s periodic reports on Form 10-Q and Form 8-K. Myogen does not undertake any obligation to update any forward-looking statements contained in this document or the anticipated presentation as a result of new information, future events or otherwise. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release or the presentation. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected.

Financial projections entail a high level of uncertainty due, among many factors, to the variability involved in predicting clinical trial enrollment rates, availability, terms and timing of additional financing transactions and the potential for Myogen to enter into additional licensing or strategic collaborations. Myogen is at an early stage of development and may not ever have any products that generate significant revenue. The Company`s results may be affected by its effectiveness at managing its financial resources, its ability to successfully develop and market current and new products, difficulties or delays in its clinical trials, difficulties or delays in manufacturing its products, and regulatory developments involving current and future products. Delays in clinical trials, whether caused by adverse events, patient enrollment rates, regulatory issues or other factors, could adversely affect the Company`s financial position and prospects. Results from earlier clinical trials are not necessarily predictive of future clinical results. The Company plans on updating financial guidance for 2004 when it releases results for each quarter or upon the announcement of material corporate events.




--------------------------------------------------------------------------------
Source: Myogen, Inc.

[bioperformer]

INSIDERTRADING - ein paar ganz interessante Zahlen hierzu....



http://http://www.insidertrading4u.com/it.php?v=Jk1g52raW8ut…



Wen wundert es da noch, daß MYOG so richtig schön ins Laufen kommt, aktuell 8,10 US$ (+ 10,2%) ...

[bioperformer]

sorry, muß mich da nochmals zurücknehmen, reiche das aber noch nach.

[therman]

TOP INSTITUTIONAL HOLDERS

Holder - - Shares - - % - - Out Value - - * Reported
Perseus, L.L.C. - - 1,677,602 - - 6.33 - - $12,984,639 - - 30-Jun-04
Soros Fund Management LLC -- 1,677,602 - - 6.33 - - $12,984,639 - - 30-Jun-04
FMR Corporation (Fidelity Management & Research Corp) -- 908,400 - - 3.43 - - $7,031,016 - - 30-Jun-04
RS Investment Management, L.P. - - 534,800 -- 2.02 - - $4,139,352 - - 30-Jun-04
JP Morgan Chase & Company - - 4,237,423 - - 15.98 - - $32,797,654 - - 30-Jun-04
Deephaven Capital Management,LLC´ - - 497,818 - - 1.88 - - $3,853,111 - - 30-Jun-04
UBS Global Asset Management - - 477,190 - - 1.8 - - $3,693,450 -- 30-Jun-04
Barclays Bank Plc - - 348,222 - - 1.31 - - $2,695,238 - - 30-Jun-04
Price (T.Rowe) Associates -- 314,500 - - 1.19 - - $2,434,230 - - 30-Jun-04
Citigroup Inc. - - 213,600 - - 0.81 - - $1,653,264 - - 30-Jun-04

[bioperformer]

...leider ist mir da heute morgen mit der Direktverlinkung zum Thema Insidertrading ein kleines Malheur passiert, der allerdings wichtigste Teil daraus im Anschluß nachgereicht:




INSIDER TRANSACTIONS OF
MYOGEN INC (NASDAQ: MYOG )



Date Insider Transaction Type Shares Price Value
2004-09-29 MITCHELL DANIEL J
Director Purchase 20,720 $6.50 $134,680
2004-09-29 MITCHELL DANIEL J
Director Purchase 4,144 $0.12 $497
2004-09-29 MITCHELL DANIEL J
Director Purchase 745,565 $6.50 $4,846,172
2004-09-29 MITCHELL DANIEL J
Director Purchase 149,113 $0.12 $17,894
2004-05-12 MITCHELL DANIEL J
Director Award 7,500 $0.00 $0





Bei dieser Gelegenheit noch Danke @therman für`s Aushelfen mit den Zahlen

[Mr.Arrogance]

MYOG scheint nicht uninteressant, zumal die tatsache, daß die insider die aktuelle kapitalerhöhung mittragen... cash reicht nun auch bis anfang 2006.

dennoch besteht kein anlass zur euphorie, und ein investment ist äußerst riskant.
zunächst einmal sollte man den gesamten CVD-markt analysieren (bin gerade dabei, da ich ebenfalls einige titel auf der watchlist habe), um dann jene werte mit dem besten chance-risiko profil herauszufinden.

das wichtigste produkt für MYOG ist enoximone.
ende 2004 soll das enrollment der CHF-trials beendet sein, und mitte 2005 erste vorläufige ergebnisse vorliegen.
ein kleiner pluspunkt für MYOG ist, daß enoximone in intravenöser form für eine nischenindikation in europa bereits zugelassen ist, umsätze im letzten quartal 900.000 $.
das risiko einer nicht-zulassung ist jedoch recht hoch einzuschätzen, wenn man die ergebnisse des begleitenden phaseIII-trials EMOTE betrachtet, die im märz bekannt wurden und zum kurseinbruch führten. hier konnte bei den primären zielen keine signifikanz erreicht werden, insbesondere verschreckte die tatsache, daß in der enoximone gruppe 7 patienten mehr verstarben als in der placebo gruppe.
dies muß nicht das endgültige aus für enoximone bedeuten, die ergebnisse bezogen sich auf einen 30-tage zeitraum und 201 patienten, alle in weit fortgeschrittenem CHF-stadium, im gegensatz zu den relevanteren ESSENTIAL-trials.

mr.A

[bioperformer]

Moin Moin Mr.Arrogance,

irgendwie verstehe ich nicht so ganz was du uns mit deiner Aussage bezüglich der Testergebnisse vom März - und des damals damit verbundenen Kurseinbruchs von ca. 17 auf 10 US$- näherbringen willst.
Bedenke dabei erstens, daß sich im weiteren Verlauf der damaligen Negativschlagzeilen das Kursniveau von 10 US$ nochmals annähernd halbierte, auch daß inzwischen bereits ein halbes Jahr vergangen ist. Niemand wird also deshalb noch schockiert seine Shares abverkaufen...

Mag sein, daß zu den doch zuletzt deutlich positiveren News noch das mehrfach von mir angesprochene Shortcovering hinzukam und so der Kurs doch recht beachtlich nordwärts getrieben wurde.

Vermutlich wird dieser Tage schon manch einer ein paar schnellverdiente Kröten mitnehmen. Besonders heftige Einbußen sehe ich da aber nicht auf uns zukommen, zumal die Käufer der neuen Shares sich den Kurs nicht runterzocken lassen werden.

[Mr.Arrogance]

moin bioperformer,
was gibt es da nicht zu verstehen?

meine aussage war eindeutig:
"das risiko einer nicht-zulassung ist jedoch recht hoch einzuschätzen"

habe nichts zur kurzfristigen kursentwicklung gesagt...

[bioperformer]

NACHTRAG ZU INSIDER TRANSACTIONS



habe zu meinem Posting vom 01.10.04 noch nachzureichen daß nicht nur DANIEL MITCHELL shares für knapp 5 Mio.US$ gekauft hat, sondern auch ein gewisser Herr ARNOLD L. ORONSKI,PH.D.
Das wäre weiter nicht außergewöhnlich, wenn es sich bei der Summe die er da so investiert hat nicht um weitere 5 Mio. US$ handeln würde.

Wie man unschwer erkennen kann, scheint das die Kauflust nicht gerade einzudämmen. Befasst man sich jedoch mal mit dem geradezu durchorganisiert wirkenden Kaufverhalten, bleibt den genaueren Betrachtungen manch möglicher Zusammenhang nicht verborgen.

Langsam gewinne ich den Eindruck, daß neben den allseits gegenwärtigen Gruppierungen Longs und Shorties hier noch eine dritte "Mannschaft" mitspielt, die der AUFKÄUFER.

Ziel derer ist entweder möglichst große Anteile aus dem Freefloat aufzukaufen um so gewisse Gewichtungen in der Verteilung von Anteilen bei einer möglichen Übernahme vorzubereiten. Hinsichtlich möglicher P3-Ergebnisse nicht unclever, wenn man bereits mit diesen plant.

Schon mal eine Überlegung wert oder?

[Mr.Arrogance]

moin bioperformer,
auch hier muß ich wieder etwas wasser in den wein gießen..

die von dir erwähnten insidertransaktionen am 29.09. waren keine käufe aus dem freefloat... das war die $60 mio kapitalerhöhung.
dennoch kann man das ganze sicherlich positiv sehen...

die genannten herren durften sich jedoch mit deutlichem premium zum markt eindecken.

interessanter ist vielleicht, das jerry jackson gestern am markt gekauft hat, und zwar für etwa 200.000$...

[bioperformer]

hallo Mr.Arrogance,


wie mir scheint treffen unsere Meinungen hier des öfteren aufeinander,was ja nicht bedeuten muß, daß da nichts konstruktives bei rauskommt. In diesem Sinne also zuerst mal guten Abend und zur Sache.


Du hast natürlich recht mit dem Hinweis, das sowohl die Käufe von DANIEL MITCHELL, wie auch die von ARNOLD L. ORONSKI -die beiden Herren mit den 5 Mio. Engagements- nicht aus dem Freeflow sondern aus dem Premium bedient wurden.
Ich ging davon aus, daß sich das bereits am Kurslevel von 6,50 US$ deutlich erkennen ließ. Ok, Fehler lag bei mir, hätte das noch deutlicher rüberbringen sollen.

Aus den weiteren Käufen der letzten Tage hebt sich - du hast es bereits angesprochen- mal wieder ein Insiderkauf größerer Hausnummer hervor:


2004-10-04 JACKSON JERRY T
Director Purchase 900 $8.42 $7,578
2004-10-04 JACKSON JERRY T
Director Purchase 6,800 $8.36 $56,848
2004-10-04 JACKSON JERRY T
Director Purchase 200 $8.44 $1,688
2004-10-04 JACKSON JERRY T
Director Purchase 5,300 $8.38 $44,414
2004-10-04 JACKSON JERRY T
Director Purchase 4,720 $8.40 $39,648
2004-10-04 JACKSON JERRY T
Director Purchase 300 $8.43 $2,529
2004-10-04 JACKSON JERRY T
Director Purchase 2,200 $8.37 $18,414
2004-10-04 JACKSON JERRY T
Director Purchase 1,780 $8.49 $15,112
2004-10-04 JACKSON JERRY T
Director Purchase 2,800 $8.39 $23,492



Ist doch auch nicht gerade von schlechten Eltern oder?


PS: Ist da deiner Meinung nach nicht doch was im Busch, weil normal ist das nicht...

[Mr.Arrogance]

ja, ich habe die befürchtung, das was im busch ist...

an der börse bin ich von natur aus sehr mißtrauisch... das hat mich sehr oft vor reinfällen bewahrt, und selten einmal hat mich die vorsicht große gewinne gekostet...

mir kommt die ganze sache merkwürdig vor, und ich habe mir die insiderkäufe der kapitalerhöhung nochmal angeschaut.
der kaufkurs lag bei knapp $5,44!
warum versucht man das zu verschleiern?
warum versucht man einen kaufkurs von 6,50 zu suggerieren?

oronsky z.b. hat genau das gleiche paket erworben wie mitchell... bei ihm sind 10 käufe angegeben, bei mitchell vier... alles krumme zahlen.

mir ist die sache zu heiss, ich werde morgen aussteigen.

[bioperformer]

Mr.Arrogance,



wie kommst du beim Kaufkurs von MITCHELL und ORONSKY auf die Zahl 5,44 per share ?

Habe ich da was übersehen?




Bio

[Mr.Arrogance]

nicht nur bei mitchell und oronsky... bei allen.
war wohl so geregelt, daß es für je 5 aktien zu 6,50 eine zu 0,12 gibt...

[Mr.Arrogance]

halt, alles zurück!
das kann nicht sein... würde auch sofort auffliegen.

hab nochmal die meldung richtig gelesen... es handelt sich dabei natürlich um die warrants, ist also noch gar keine verwässerung.
hatte mich schon gewundert, weil ich auf über 11 mio neue shares kam. so sind es also tatsächlich zunächst nur 9,8 mio neue...
bin doch etwas müde...

[Mr.Arrogance]

aaahhhh... 9,2 mio neue!
gute nacht!

[bioperformer]

@Mr.Arrogance,


Moin,Moin ...


hab mir das mit den Warrants gestern nochmals bei Myogen bestätigen lassen.
Lob an die PR-Abteilung - Antwort erfolgte prompt, was ja leider anderswo auch nicht immer gewährleistet ist.

[bioperformer]

LANGSAM ABER SICHER WIRD DAS SCHON.....



ich glaube ich habe da nicht zuviel versprochen



Donnerstag, 7. Oktober 2004 | 14:37 Uhr







Global Biotech Investing: Spektakuläre Insiderkäufe bei MYGON!

Die vielleicht spektakulärsten Insiderkäufe im Biotech-Sektor beobachten wir aktuell bei MYOGEN! Unternehmensinsider haben sich in den vergangenen Wochen mit Aktien im Wert von fast schon unglaublichen USD 93 Mio. eingedeckt! Und da mischen derzeit nicht nur die zum Unternehmens gehörende Personen mit, auch institutionelle Anleger sind bei MYOGEN mittlerweile dick dabei: Allen voran JP Morgan, die mit einem Anteil von 4.3 Mio. Aktien den größten institutionellen Einzelaktionär stellen. Über die Hälfte der ausstehenden Aktien sind derzeit in festen Händen, Ende des vergangenen Monats hatte das Unternehmen überhaupt keine Probleme, eine USD 60 Mio.-Finanzierung im Rahmen eines Private Placements zu platzieren. Was veranlasst diese Investoren zu einem Engagement in der Aktie, die erst seit gut einem Jahr an der Börse notiert ist?

Analysten schätzen, dass MYOGEN per 2007 den Break-Even erreichen und schon im Folgejahr einen Gewinn je Aktie von bis zu USD 2.30 erreichen kann! Das KGV läge dann bei knapp 4, das Kurspotenzial im Vervielfachungsbereich! Momentan treiben jedoch in erster Linie die Insiderkäufe den Kurs nach oben und das ordentlich: Von den Jahrestiefs um USD 5.20 im September schoss der Wert in den vergangenen 3 Wochen um spektakuläre 65% nach oben! Springen Sie sofort mit einer Position auf diese Rallye auf! (WKN 592 817)



immer alles nachmachen....

[Mr.Arrogance]

obwohl ich bei den insidertrades zunächst ein paar gespenster gesehen habe... ich bin gestern erstmal raus.

schön und gut, die insider haben die kapitalerhöhung getragen... aber von den ESSENTIAL resultaten können die auch nichts wissen. außerdem benötigte myog das geld dringend, sonst wär im frühjahr ende gewesen.
was die insider hinter den kulissen machen, wissen wir auch nicht...

was ist das für ein verein, global biotech investing?
schreiben völligen unsinn. miserabel recherchiert, da waren wir hier schon weiter... die "93 mio" sind natürlich die 60 mio kapitalerhöhung, die käufe am 29.09.
der schreiberling kommt auf 93 mio... richtig, kam mir auch merkwürdig vor, sind sehr verwirrend, diese auflistungen der insidertrades. tatsächlich ergeben die vom 29.9. 93 mio in der summe, also sind hier offensichtlich doppelnennungen dabei... sowas kommt häufiger vor. wie auch die tatsache, das warrants hier einfach als shares aufgeführt werden, wie von mir zunächst übersehen.
durch diese insgesamt für die öffentlichkeit etwas undurchsichtige darstellung der insiderkäufe wird natürlich auch eine euphorie geschürt, die den kurs treibt...

ein weiterer punkt ist, das die geschichte natürlich auch eine ganz schöne verwässung ist... 9,2 mio zusätzliche aktien, also mal eben so um die 80 mio marktkapitalisierung drauf...

[bioperformer]

hallo Mr.Arrogance,


....wust` ich`s doch daß ich bald wieder von dir höre...




Thema heute: Marktkapitalisierung und Verwässerung


...laß uns gemeinsam nochmals ein paar Eckdaten besprechen. Da wäre zum einen das finanzielle Polster, das Myogen vor dieser ganzen Aktion hatte - nach meinen Zahlen war das ein Betrag zwischen 2,9 und 3,0 US$ per Share. Insgesamt waren das also ca. 77 Mio. US$ die dem Unternehmen derzeit noch zur Verfügung standen. Bei ca. 15 Mio. Cashburn per Quartal wäre da also durchaus bequem noch Wegzehrung für ein komplettes Geschäftsjahr gewesen.
Von knappen Geldern kann also durchaus nicht gesprochen werden, es sei denn du meintest das Frühjahr 2006.

Die Verwässerung, die du beschreibst ist eigentlich keine, wenn man mal den jetzigen Vermögensbestand von grob 137 Mio. US$ durch die jetzt vorhandenen 35 Mio. Shares dividiert, bekommt man ziemlich exakt 3,91 US$ als Ergebnis.
Demnach hat die Kapitalerhöhung eigentlich eher zu einem Vermögenszuwachs per Share geführt.

Die derzeitige Marktkapitalisierung hat doch nichts mit dem Erlös aus der Kapitalerhöhung zu tun, sondern errechnet sich aus dem aktuellen Aktienpreis X 35.000.000, ist also nicht centgenau zu berechnen da der Preis der Shares ja flexibel ist.

Was der nun ganz exakte Zuwachs an Marktkapitalisierung auf Grund der Kapitalerhöhung ist, dürfte sowieso schwer zu berechnen sein, weil du den theoretischen Kurs ohne Kapitalmaßnahme zu jetzigen Zeitpunkt nicht festlegen kannst.


....ist doch ganz einfach oder?

[Mr.Arrogance]

moin,
bin auch mal wieder hier...

das finanzielle polster...
du hast sicher die pressemeldung vom 28.09. gelesen... dort sagt myog selbst, daß sie durch die zusätzlichen $60 mio nun in der lage sind, bis ende 2005 das geschäft zu finanzieren... das ist im übrigen auch der zeitpunkt, wo mit ergebnissen der ambrisantan-studie zu rechnen ist.

es ist also nicht einfach der aktuelle quartalsverlust hochzurechnen und vom cash abzuziehen. der cashburn ist bei den biotechs sehr schwankend und immer abhängig von den einzelnen entwicklungsprojekten. für das enrollment in der ambrisentane-studie z.b. wurde der kostenaufwand gerade deutlich erhöht, um die timeline komplettes enrollment mitte 2004 einzuhalten, da man hier mit sinkenden patientenzahlen und konkurrenzstudien zu kämpfen hat...

zum thema verwässerung:
35 mio shares waren es meines wissens vor der kapitalerhöhung, werde das nochmal verifizieren... ansonsten wäre prozentual gesehen die verwässerung noch deutlich größer.
in meinen augen ist es eindeutig eine verwässerung, wenn ich mögliche zukünftige gewinne (und nur wegen diesen kauft man den titel) durch knapp 30% mehr aktien teilen muß... daß man zunächst einmal auch 60 mio mehr cash hat, ist selbstverständlich, führt jedoch keineswegs dazu, daß eine aktie mehr wert ist, denn du mißt der aktie ja eine wert zu, der deutlich über dem cashbestand liegt.
zunächst einmal kommt in diesem fall durch die aktien der kapitalerhöhung natürlich erstmal mehr cash/aktie herein, nämlich gut 6$... die alten aktien haben ein cash/aktie von 2,2 (nach meiner rechnung), dann liegt nach der kapitalerhöhung der cash/aktie bei 3,1.
alle anderen werte, und das sind die entscheidenden, nämlich die werte, die du der pipeline zugestehst, müssen durch 9,2 mio zusätzliche aktien geteilt werden.
der cashbestand ist sowieso nur eine momentaufnahme und wird für die entwicklung der pipeline aufgebraucht... also wird immer, wenn ich erneut den kapitalmarkt anzapfen muß, der eigentliche wert verwässert.

gruß mr.A

[Mr.Arrogance]

so, ich hab nochmal nachgesehen.
bioperformer, deine zahlen sind in etwa richtig, es waren tatsächlich ende des 2. quartals nur 26,5 mio shares, jetzt sind es 35,7 mio.
damit waren es vor der ke nicht 2,2 cash/aktie (bei yahoo sind also die neuen aktien bereits aktualisiert, das cash jedoch nicht), sondern 2,9. die verwässerung ist also noch größer, als ich angenommen habe, +34% neue aktien.
nach der ke haben wir damit 35,7 mio shares und 3,8 cash/aktie (wobei man eigentlich noch 2-3 mio commission an die ke-banken abziehen muß).

alles weitere aus meiner anmerkung kann so stehen bleiben.

[bioperformer]

....endlich,


hatte aber noch Hoffnung, daß längst noch nicht alle Klarheiten restlos beseitigt sind


Bitte differenziere zwischen Gewinn per Share, Cash per Share und Shareholder Equity, was gleichbedeutend dem Gesamtvermögen des Unternehmens ist.

Ein hohes Gesamtvermögen ist nicht grundsätzlich mit hohem Cashbestand verbunden, es gibt ja die verschiedensten Arten von Vermögenswerten - Liegenschaften z.B. oder dergleichen.

Anhand einfacher Berechnung - Dreisatz nannte man das wohl- ist es doch nicht allzuschwer die drei o.g. praxisnah zu ermitteln, vorausgesetzt man schmeißt nicht Äpfel mit Zwiebel in einen Sack.

Laut Q2/04 wies MYOG zum 30.06.04 Shareholder Equity in Höhe von 77.067.890 US$ aus. Des Weiteren fiel ein tatsächlicher Verlust von 13,210 Mio. oder 0,498 US$ per Share an. Die Basismenge an bewerteten Shares betrug exakt 26.490.954 Stücke.
Tatsächliche Ausgaben incl. aller Nebengeräusche lagen bei 15,631 Mio. US$ und wahrscheinlich keinem Cent mehr, sonst wäre das bei der dort praktizierten Prüfgenauigkeit der Börsenaufsicht sicher aufgefallen.

Ein tatächlicher Gewinn wird logischerweise bei mehr zugrundegelegten Shares geringer pro Share ausfallen als noch vor der Kapitalerhöhung, im Falle des noch anfallenden Verlustes reduziert sich dieser auch pro Share, weil er ja von mehr Schultern getragen wird.

Anders ist das beim Gesamtvermögen. Das vergrößert sich doch erstmal um genau den Betrag, der durch die Kaitalerhöhung eingenommen wurde.

Jetzt zu deinem wohl größtem Denkfehler bei dieser Sache und dessen einfacher Lösung:

Angenommen du hast 100 Eier und jedes ist 1 Euro wert.
Dann kaufst du noch 50 Eier a` 2 Euro hinzu.

Hat dann der Durchschnittswert der 150 Eier gegenüber den vorher gehorteten 100 St. zugenommen oder nicht ?

Genau so ist das auch mit dem Cash- bzw. Vermögenswert pro Share wenn du so willst. Zu den - wie wir wissen lt. Q2/04 vorhanden Shares kamen 9,2 Mio. Stücke hinzu, welche vereinfacht gesagt 60 Mio. Cash in die Kasse spülten.
Daraus kann abgeleitet werden daß der jetzt vorhandene Vermögenswert ca. 137 Mio. US$ oder wenn du so willst ca. 3,90 beträgt. Der Cashwert ist sicherlich etwas kleiner, da ich davon ausgehe daß hier ein paar andere Vermögenswerte miteinbezogen wurden.

Zum Schluß vielleicht noch ein kleiner Tip zur schnellstmöglichen Aussage über die komplett angefallenen, auch die gesamte R+D Schiene beinhaltenden Kosten pro Quartal - Total costs and expenses

[Mr.Arrogance]

mir scheint, du hast meinen beitrag nicht richtig gelesen, oder zumindest meine aussage nicht verstanden.

die zahlen, die du noch einmal wiederholst, über die sind wir uns weitgehend einig, stehen in keinem widerspruch zu meinem beitrag.

[bioperformer]

@Mr. Arrogance


...liegt nicht am Verstehen, sondern an zeitlicher Uberschneidung. Mit anderen Worten - mein Posting #48 entstand als Resonanz auf deine #46. Vor Absendung genannter #48 habe ich nicht deine inzwischen nachgelegte #47 registriert.....


Gruß Bio

[bioperformer]

@all


KURZE ZUSAMMENFASSUNG DER LETZTEN WOCHE



So wie es ausssieht, hat MYOGEN die erste größere Hürde auf dem Weg nach Norden geschafft.
Dies nicht nur charttechnisch - dazu später mehr-, sondern in erster Linie wenn man so will das Investorenvertrauen zurückerobert. Eigneten sich die Shares in den letzten Monaten doch eher für beste Shortdeals, dürfte hier mittel- bis langfristig wohl eher mit Long-Spekulation Geld zu verdienen sein.

Die ganz mutigen, die hier im Bereich von 5,30 US$ einstiegen, haben bereits ca. 55% Kursplus zu verzeichnen. Die breitere Masse dürfte wohl im Bereich von 6,50 - 7,00 US$ zugeriffen haben, was bis dato immerhin auch lockere 25% Zuwachs brachte.

Wie schon in meinem Posting vom 04.10.04 erklärt, habe ich zwar leichte Gewinnmitnahmen für die letzten Tage erwartet, der große Verkaufsdruck blieb erwartungsgemäß aus genannten Gründen aus.

Was bringen die nächsten Tage?
Von der Newsseite des Unternehmens selbst vermute ich nach den doch eher bewegten letzten Tagen wenig Neues. Die doch mehr als außergewöhnlichen Insiderkäufe der vergangenen Tage dürften als richtungsweisendes Zeichen sowieso auf kurze Sicht nur schwer zu toppen sein.

Interessant sollte es da eher um die Bewertung des Unternehmens durch größere Investmenthäuser infolge des doch rapide angestiegenen Bekanntheitsgrades von MYOG werden.

Vor einiger Zeit habe ich schon darauf verwiesen, daß die Unternehmensanteile phasenweise regelrecht in die Depots der großen Adressen geprügelt werden.
Mittlerweile ist klar warum.
Als nächstes dürfte -nachdem auch die charttechnische Situation eine doch sehr einladende Figur macht- die massive Einstiegsempfehlung der Analysten besagter größerer Häuser erfolgen.

Aus oben angesprochener charttechnischer Sicht zeichnet sich da wohl nach Bestätigung der Marke um 8 US$ ein baldiger Angriff auf die Gegend im Bereich von 10,50 US$ ab, was auch zugleich mein kurzfristiges Kursziel darstellt.

[therman]

Hi,

ich halte eine Konsolidierung bei MYOG für möglich.

Sie könnte bis ca. 7 - 6,8 $ gehen.

Dies wäre eine gute Gelegenheit zum Aufstocken.

therman

[therman]

Hi,

wie erwartet konsolidiert MYOG den Anstieg der letzten
Wochen.

Ich rechne mit einem Rückgang bis ca. 7$.
Hier könnte dann ein Abprall nach oben erfolgen.

Eine sehr gute Gelegenheit um neu einzusteigen oder
nachzukaufen.
Meiner Meinung nach hat MYOG langfristig enormes Potential.

therman

[bioperformer]

hallo therman,


...schau doch mal wie sich unser Baby jenseits des großen Teiches vom Tagestief erholt.

Ich denke, die Gelegenheit werden wohl ein paar Unerschrockene genutzt haben, zumal MYOG laut Aussage des Global Biotech Investing gestern in deren Musterdepot aufgenommen wurde....


Gruß bio

[bioperformer]

@all


..zum Thema der prognostizierten Kaufempfehlungen...




Upgrade Top BUY - Tgt $15.00



14-Oct-04
08:46 MYOG Myogen upgraded to Buy at Lazard; tgt $15 (8.03 )

Lazard upgrades MYOG to Buy from Hold, saying the stock`s valuation offers a compelling risk/reward scenarioning. Firm says the recent $60 mln offering provides enough capital to fund operations through 1H06, and they believe that the EMOTE disappointment is not predictive of the ESSENTIAL I and II outcomes, which they expect in 1Q05. Firm notes that MYOG now has three compounds in late-stage clinical testing, each of which offers event catalysts over the next 12 months. Maintains $15 tgt.

[bioperformer]

@all



Nachdem sich in den letzten Tagen bereits andeutete, daß uns der Bereich um 8 US$ als wohl tragfähiges Sprungpodest dienen wird, scheint sich jetzt genau dieses Szenario zu realisieren.
Viele Shorts der letzten Tage werden meiner Ansicht nach bei 8,50 bis 8,60 US$ gecovert werden, um den so entstehenden Verlust noch unter der 5%-Marke zu halten.



grüße, Bio

[bioperformer]

@all



GEWINNE MITNEHMEN.....


scheint das Motto dieser Tage bei MYOG zu sein.

In Anbetracht des doch nicht unerheblich nordwärts gewanderten Kurses von MYOG sind seit zwei Tagen erste Gewinnmitnahmen zu verzeichnen. Da die Shares vom Tiefstand bei 5,23 US$ zum Höchstkurs vom Freitag bei 9,74 US$ mittlerweile über 86% Kursplus aufwiesen, verwundert das nicht so richtig wirklich, wenn hier auch mal Kasse gemacht wird.
Fundamental liegen keine negativen News vor, die den wohl zu erwartenden kurzfristigen Trendwechsel rechtfertigen.

Diese Kursberuhigung bietet dann wahrscheinlich im Bereich von 7,00 - 7,50 US$ letztmalig in 2004 eine Kaufgelegenheit für alle, die es verpennt hatten sich rechtzeitig zu positionieren.




Grüße,Bio

[bioperformer]

@all



Press Release Source: Myogen, Inc.


Myogen Reports 2004 Third Quarter Results
Wednesday November 3, 6:00 am ET


DENVER, Nov. 3 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG - News), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today reported 2004 third quarter results. As of September 30, 2004, the Company had cash, cash equivalents and investments of $132.2 million. Net loss attributable to common stockholders for the three months ended September 30, 2004 was $13.0 million, or $0.49 per share, compared with $52.3 million, or $50.29 per share, during the same period in 2003. Net loss attributable to common stockholders for the nine months ended September 30, 2004 was $42.2 million, or $1.59 per share, compared with $79.5 million, or $76.99 per share, during the same period in 2003.
"We continue to execute the development plans for our three product candidates," said J. William Freytag, President and Chief Executive Officer of Myogen. "We are gratified by the support and confidence the investment community expressed in Myogen`s product pipeline, management and development plans with the completion of our $60 million financing in late September. With patient enrollment completed in the two Phase III registration trials for enoximone and progressing in the Phase III registration trials for ambrisentan and the Phase IIb study of darusentan, we are looking forward to next year when we expect to obtain important clinical trial results for all three product candidates."

Product Portfolio Update

Enoximone:
* ESSENTIAL I & II, the two pivotal Phase III trials evaluating
enoximone capsules in patients with chronic heart failure, continue to
progress in line with expectations. In May, the Company announced the
completion of enrollment of 1,800 patients for the two trials, with
patient treatment to continue until 956 patients have had a primary
endpoint event (cardiovascular hospitalization or all-cause
mortality). The Company expects that patient treatment in both trials
will be completed by the end of this year. At that time, the mean
patient treatment period will exceed 18 months. The Company expects
to report preliminary, top-line results mid-year 2005.

* EMOTE, a non-pivotal Phase III trial of enoximone capsules in 201
patients in advanced stages of chronic heart failure who are dependent
on intravenous (i.v.) inotrope therapy, was completed in February 2004
and preliminary results were reported in March 2004. Additional
results were presented at the 8th Annual Scientific Meeting of the
Heart Failure Society of America on September 15, 2004 in Toronto,
Canada.


* EMPOWER, an additional non-pivotal Phase III trial designed to provide
potential marketing support, began enrollment in September 2003.
Trial enrollment continues to progress, but remains slower than
projected. The Company continues to monitor the viability of the
trial.


The Company believes that if the ESSENTIAL trials are successful, the results will be adequate to support regulatory submission for enoximone capsules in the United States as well as in certain international markets. Although the Company does not believe that EMOTE or EMPOWER will be required for regulatory approval, it believes these studies may assist in regulatory and post-approval marketing efforts.

Ambrisentan: In January 2004, Myogen announced the initiation of patient enrollment in ARIES 1 & 2, the two pivotal Phase III trials evaluating ambrisentan in pulmonary arterial hypertension. The Company`s goal is to complete patient enrollment in the ARIES trials by the end of the first half of 2005. In August 2004, the Company announced that it was adding additional resources to aid enrollment rates in the trials, which were lower than originally expected due to a number of factors, including declining numbers of patients with PAH who are treatment naove seen at clinical trial sites as well as competing trials. Preliminary indications suggest that the Company`s initiatives to accelerate enrollment to meet this target are having a positive effect, although several additional months will be required in order to provide clarity on the Company`s ability to meet its enrollment timing goal. The Company expects to report preliminary results of the trials approximately six months after the completion of patient enrollment. The United States Food and Drug Administration (FDA) has granted orphan drug designation to ambrisentan for the treatment of PAH.

Darusentan: In July 2004, the Company announced the initiation of a Phase IIb clinical trial to evaluate the safety and efficacy of darusentan in patients with resistant systolic hypertension. Enrollment in the 105 patient trial is progressing in line with expectations. The Company currently expects the trial to be completed mid-year 2005.

The primary objective of the randomized, double-blind, placebo-controlled trial is to determine if darusentan is effective in reducing systolic blood pressure in patients with resistant systolic hypertension. Resistant hypertension is defined by The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure sponsored by the National Institutes of Health (JNC7) as the failure to achieve goal blood pressure in patients who are adhering to full doses of an appropriate three-drug regimen that includes a diuretic. Approximately 105 patients will be randomized to darusentan or placebo at approximately 30 investigative sites. Patients will undergo forced titration every two weeks through 10, 50, 100 and 150 mg of darusentan or placebo until the target dose of 300 mg once a day is achieved. The treatment period for the study is 10 weeks.

2004 Third Quarter Financial Highlights

On September 29, 2004, the Company closed on a Private Investment in a Public Entity (PIPE) financing, in which 9,195,400 of new shares of common stock and warrants exercisable for 1,839,080 shares of common stock were issued to institutional and accredited investors for total net proceeds of $57.2 million. The warrants have an exercise price per share of $7.80.

Sales of Perfan I.V. for the three months ended September 30, 2004 were $783,000 versus $707,000 for the same period in 2003. The increase in sales from the prior year period was the result of a more favorable exchange rate. The cost of Perfan I.V. sold as a percentage of sales was 31% for both the three months ended September 30, 2004 and 2003. For the three months ended September 30, 2004, research and development contracts revenue from our research agreement with Novartis was $1.7 million.

Research and development expenses, excluding stock-based compensation expenses, increased 75% to $12.3 million from $7.1 million for the three months ended September 30, 2004 and 2003, respectively. The increase in expenses for the period was primarily due to costs associated with increased patient enrollment in the ESSENTIAL and ARIES trials and costs for initiation of the darusentan Phase IIb trial.

Selling, general and administrative expenses, excluding stock-based compensation expenses, increased 215% to $2.1 million from $663,000 for the three months ended September 30, 2004 and 2003, respectively. The increase was primarily due to an increase in insurance and professional service costs related to being a public company during the current year period and an increase in staffing and related recruiting costs.

2004 Financial Guidance

Financial projections entail a high level of uncertainty due, among many factors, to the variability involved in predicting clinical trial enrollment rates, availability, terms and timing of additional financing transactions and the potential for Myogen to enter into additional licensing or strategic collaborations. The Company plans on updating financial guidance for 2004 when it releases results for each quarter or upon the announcement of material corporate events.

Based upon results through the third quarter, the Company is updating its financial guidance. For the year ending December 31, 2004, the Company presently anticipates:

* Total product sales of $3.1 million to $3.3 million, an upward
revision from previous guidance of $2.8 million to $3.3 million;
* Total operating expenses, excluding stock-based compensation expenses,
of $62 million to $65 million, a downward revision from previous
guidance of $62 million to $75 million; and,
* Basic net loss per share between $2.10 and $2.30, a reduction in
anticipated net loss compared to previous guidance of between $2.30
and $2.76.


In addition, based on current spending projections, the Company believes its cash, cash equivalents and investments are sufficient to fund operations at least through the end of 2005.

2005 Milestones

Myogen is working towards several significant milestones in the coming year, including:

* Completion of ESSENTIAL I & II (enoximone pivotal Phase III) with
preliminary, top-line results to be reported mid-year 2005;
* Completion of the Phase IIb trial of darusentan in resistant systolic
hypertension;
* Completion of patient enrollment in ARIES-1 & 2 (ambrisentan pivotal
Phase III) by the end of first half of the year; and
* Completion of ARIES trials with top-line results to be reported
approximately six months after completion of patient enrollment.


Conference Call

J. William Freytag, President and CEO, and other members of Myogen`s senior management will provide a company update and discuss results via webcast and conference call on Wednesday, November 3, 2004 at 4:30 pm Eastern. To access the live webcast, please log on to the company`s website at www.myogen.com and go to the Investor Relations section. Alternatively, callers may participate in the conference call by dialing 800-366-7417 (domestic) or 303-275-2170 (international). Webcast and telephone replays of the conference call will be available approximately two hours after the


completion of the call through Friday, November 19, 2004. Callers can access
the replay by dialing 800-405-2236 (domestic) or 303-590-3000 (international).
The passcode is 11013200#.

About Myogen

Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. Myogen currently markets one product in Europe for the treatment of acute decompensated heart failure and has three product candidates in late-stage clinical development: enoximone capsules for the treatment of chronic heart failure, ambrisentan for the treatment of pulmonary arterial hypertension and darusentan for the treatment of resistant hypertension. The Company also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders. Please visit Myogen`s website at www.myogen.com.

Safe Harbor Statement

This press release contains forward-looking statements that involve significant risks and uncertainties, including those discussed in this release and others that can be found in the "Risk Factors" section of Myogen`s Annual Report on Form 10-K for the year ended December 31, 2003, Myogen`s Form S-3 filed on October 29, 2004 and in Myogen`s periodic reports on Form 10-Q and Form 8-K. Myogen is providing this information as of the date of this release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected. The Company`s results may be affected by its effectiveness at managing its financial resources, its ability to successfully develop and market current and new products, difficulties or delays in its clinical trials, difficulties or delays in manufacturing its products, and regulatory developments involving current and future products. Delays in clinical trials, whether caused by adverse events, patient enrollment rates, regulatory issues or other factors, could adversely affect the Company`s financial position and prospects. Results from earlier clinical trials are not necessarily predictive of future clinical results. Preliminary results may not be confirmed upon full analysis of the detailed results of a trial. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue one or more of its drug development or discovery research programs. Myogen is at an early stage of development and may not ever have any products that generate significant revenue.

MYOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(Unaudited)
September 30, December 31,
2004 2003

ASSETS
Current assets:
Cash and cash equivalents $84,758,241 $44,337,721
Short-term investments 43,909,654 69,914,627
Accrued interest receivable 302,855 607,393
Trade accounts receivable 1,119,867 1,274,861
Research and development contract

amounts due within one year 1,000,000 1,625,000
Inventories 360,910 724,282
Prepaid expenses and other current assets 1,224,118 1,434,174
Total current assets 132,675,645 119,918,058

Long-term investments 3,493,384 --
Property and equipment, net 2,280,294 1,304,028
Other assets 38,847 51,238

Total assets $138,488,170 $121,273,324

LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $9,153,377 $7,594,935
Accrued liabilities 1,135,858 1,350,114
Current portion of deferred revenue 1,666,667 1,666,667
Current portion of capital lease
obligations 49,936 37,015
Current portion of notes payable,
net of discount 1,774,479 1,639,246
Total current liabilities 13,780,317 12,287,977

Deferred revenue, net of current portion 1,698,029 2,948,029
Capital lease obligations, net of
current portion 109,487 121,617
Notes payable, net of current portion
and discount 645,661 1,993,906

Stockholders` equity:
Preferred Stock, $0.001 par value;
5,000,000 shares authorized at
September 30, 2004 and December 31,
2003, no shares issued or outstanding -- --
Common stock, $0.001 par value;
100,000,000 shares authorized and
35,722,358 and 26,457,927 shares
issued and outstanding as of
September 30, 2004 and December 31,
2003, respectively 35,722 26,458
Additional paid-in-capital 286,106,160 229,080,380
Deferred stock-based compensation (3,207,096) (6,730,195)
Accumulated other comprehensive (loss)
income (3,723) 22,185
Deficit accumulated during the
development stage (160,676,387) (118,477,033)
Total stockholders` equity 122,254,676 103,921,795

Total liabilities and stockholders`
equity $138,488,170 $121,273,324


MYOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

For the Three Months Ended For the Nine Months Ended
September 30, September 30,
2004 2003 2004 2003

Revenues:

Product sales $783,235 $707,013 $2,534,713 $2,071,823
Research and
development
contracts 1,666,667 -- 4,669,962 --
2,449,902 707,013 7,204,675 2,071,823

Costs and
expenses:
Cost of
product
sold 239,917 220,192 788,621 654,138
Research and
development
(excluding
stock-based
compensation
expense of
$470,155,
$501,467,
$1,621,286
and
$1,243,861,
respectively) 12,334,697 7,052,067 39,420,805 24,621,961
Selling,
general and
administrative
(excluding
stock-based
compensation
expense of
$473,161,
$339,949,
$1,655,906
and
$862,441,
respectively) 2,085,914 662,738 6,368,042 2,564,309
Stock-based
compensation
expense 943,316 841,416 3,277,192 2,106,302
15,603,844 8,776,413 49,854,660 29,946,710

Loss from
operations (13,153,942) (8,069,400) (42,649,985) (27,874,887)
Interest
income
(expense),
net 156,412 (55,125) 465,052 (63,379)

Loss before
income taxes (12,997,530) (8,124,525) (42,184,933) (27,938,266)
Income taxes 5,034 5,530 14,421 16,165

Net loss (13,002,564) (8,130,055) (42,199,354) (27,954,431)
Accretion of
mandatorily
redeemable
convertible
preferred
stock -- (4,243,618) -- (11,583,987)
Deemed dividend

related to

beneficial
conversion
feature of
preferred
stock -- (39,935,388) -- (39,935,388)

Net loss
attributable
to common
stockholders $(13,002,564) $(52,309,061) $(42,199,354) $(79,473,806)
Basic and
diluted
net loss
per common
share $(0.49) $(50.29) $(1.59) $(76.99)
Weighted
average common
shares
outstanding 26,623,208 1,040,108 26,525,466 1,032,200




--------------------------------------------------------------------------------
Source: Myogen, Inc.

[borazon]

Da war doch keine negative Überraschung dabei, oder?
Kennt jemand einen bestimmten Grund für den Rückgang?

[bioperformer]

@borazon


..habe im Moment leider auch keine Kenntnis woran es liegt daß der Kurs so massiv nachgab...



Gruß, Bio

[bioperformer]

SHORTRATE PER 15.12.04

Dec. 15, 2004 1,461,800 108,716 13.45
Nov. 15, 2004 1,368,341 208,009 6.58
Oct. 15, 2004 917,027 118,773 7.72
Sep. 15, 2004 744,448 68,080 10.93
Aug. 13, 2004 882,614 82,646 10.68

[bioperformer]

MYOGEN (MYOG)Updates Ambrisentan Clinical Development Guidance; Myogen Plunges On Trial Delays


DENVER, Feb. 2 /PRNewswire-FirstCall/ -- Myogen, Inc. , a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today updated its guidance for the ambrisentan clinical development program.

In January 2004, Myogen announced the initiation of patient enrollment in ARIES 1 & 2, the two 186-patient pivotal Phase III trials evaluating ambrisentan in pulmonary arterial hypertension (PAH). ARIES-1 is currently being conducted in North America and Australia. ARIES-2 is being conducted in Western and Eastern Europe, Israel and South America. The company`s initial goal was to complete patient enrollment in both trials by the end of the first half of 2005. ARIES-2 continues to progress in line with prior guidance and is expected to complete enrollment by the end of June 2005. However, based on recent enrollment in ARIES-1, the company now expects enrollment in this trial will be completed in the fourth quarter of 2005. The company expects to report preliminary results of each trial approximately six months following completion of patient enrollment.

The company believes enrollment in ARIES-1 has been affected by a number of factors, including a decline in the availability of treatment naive PAH patients due to increasing market penetration of bosentan as well as the expanded use of sildenafil following the release of clinical data in October 2004. Additionally, other clinical trials are competing for this group of patients.

Myogen currently markets one product in Europe for the treatment of acute decompensated heart failure and has three product candidates in late-stage clinical development: enoximone capsules for the treatment of advanced chronic heart failure, ambrisentan for the treatment of pulmonary arterial hypertension and darusentan for the treatment of resistant hypertension. The company, in collaboration with Novartis, also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders. Please visit Myogen`s website at http://www.myogen.com/.

[Dionysius]

Gibt es noch jemanden, der wie ich die Aktie hält? Das Teil steigt seit Tagen und ich finde keine news. Hat einer eine Idee, was angesagt ist?

[[KERN]Codex]

Echt Crazy, ich verfolge sie seit 6$

[bioperformer]

Hier kommt´s jetzt gleich verschärft...

MYOG liegt mit ca. +35% vorbörslich im Geschehen

[Dionysius]

[posting]17.423.505 von bioperformer am 02.08.05 14:57:45[/posting]Bio, hast Dir eine halbjährige Auszeit in Deinem thread genommen.

Ich denke, es gibt heute und vielleicht in den nächsten noch ein paar Gewinnmitnahmen - und ich hoffe, dass es dann Ende des Monats nochmal richtig gen Norden geht

[bioperformer]

hallo Dionysius,

stimmt, liegt aber nicht daran dass mich MYOG nicht mehr interessiert, habe inzwischen einige andere Projekte angeleiert die teilweise recht zeitaufwendig waren.
Bin damals bei einem Teil meiner MYOG-Shares unglücklich ausgestoppt worden, der Teil den ich heute noch habe unterliegt jedoch keinem SL und so kann ich heute natürlich strahlen.

MYOG profitiert natürlich heute massiv von der nachfolgenden Kaufempfehlung
Update Myogen Inc.: Strong Buy
Quelle: First Albany
Datum: 02.08.05

In ihrer Analyse vom Dienstag, 2. August 2005 stufen die Analysten von First Albany die Aktie des Unternehmens Myogen Inc. von "Buy" auf "Strong Buy" herauf. Das Kursziel für die Aktie liegt momentan bei 28 $.

[Dionysius]

hey bioperformer,
natürlich ist Dir auch nicht dies entgangen:

Myogen (NasdaqNM:MYOG - News) ran up 25% after it said late Monday that it expects top line results from its ARIES-2 trial, which completed patient enrollment on July 21, by the end of 2005. The company also expects to report top line results from the Phase IIb trial for Darusentan by the end of August. Separately, the company reported a second-quarter loss of $21.5 million, or 60 cents a share, vs. a loss of $13.2 million, or 50 cents a share in the same period a year ago. Revenue fell to $2.3 million from last year`s $2.6 million.

Auswertungen der angesprochenen Aries-2 trials werden Ende des Jahres erwartet.
Aber ich glaube auch, dass heute v.a. die Bewertung von First Albany ausschlaggebend war. Die 28 Euronen weckt die Gier - soll uns aber recht sein ....

Schönen Gruss,
Dio

[bioperformer]

ist mir natürlich nicht entgangen

Nochmals kurz zum heute ausgegebenen Kursziel: hierbei handelt es sich natürlich um US$ und nicht um Euronen!

Gruß, Bio

[Fruehrentner]

Myogen "strong buy"

Rating-Update: Die Analysten von First Albany stufen die Aktien von Myogen (ISIN US62856E1047/ WKN 592817) von "buy" auf "strong buy" hoch. Das Kursziel werde von 8 auf 28 USD angehoben.

Quelle: AKTIENCHECK.DE

[Fruehrentner]

Könnte Myogen nicht auch auf dem "Radarschirm" von Big Pharma stehen und zum Übernahmekandidat werden?



PS: Ich bin (noch) nicht in Myogen investiert.

[bioperformer]

@Fruehrentner

wenn sich klar abzeichnet dass MYOG seine Zulassung - egal für welche Indikation erhält - wird das Unternehmen "einkassiert".
Leider wird das wahrscheinlich schon in den Grundzügen über die Bühne gebracht werden bevor der gemeine Kleinaktionär davon Wind bekommt. Die Ergebnisse der entsprechenden Tests sind für die Big-Player der Branche von äußerster Bedeutung und es ist davon auszugehen, dass diese auch die gewünschten Infos vorzeitig mindestens angedeutet bekommen...

[Fruehrentner]

@bioperformer

danke für deine Einschätzung.

Könnte MYOGEN aufgrund der Zahlen/fundamentalen Daten jetzt ähnlich abgehen wie derzeit VIROPHARM?

[bioperformer]

@Fruehrentner

...ist natürlich immer schwierig zu sagen x läuft jetzt wie y, weil x eben nicht y ist und auch niemals sein wird.

Vereinfacht gesagt sind beide zu grundverschieden, um jetzt vom einen auf den anderen schließen zu können. VIRO schreibt schwarze Zahlen, MYOG ist noch kilometerweit davon entfernt.
Der Markt, in dem MYOG tätig ist, dürfte als der wohl bestbezahlteste im medizinischen Bereich zu bezeichnen sein. Landet ein Unternehmen hier einen Treffer dürfte es das dann so gewesen sein mit dem finanziellen Kleinkrämertum. Die logische Konsequenz daraus liegt darin, dass Unternehmen jedoch auch bei Versagen bei Zwischen- oder gar Endzielen gewaltig von der Anlegerschaft verprügelt werden.

Nun aber nochmals zu deiner Frage nach meiner Meinung zum weiteren Kursverlauf von MYOG. So einen schön ansteigenden Kursverlauf wie bei VIRO denke ich wird es hier nicht geben. Ein beachtlicher Teil dessen, was wir heute an Kursgewinn sahen - und vermutlich auch schon wegen den anstehenden Kaufempfehlungen noch sehen werden - wird andererseits wieder durch die Herrn der shortenden Zunft aufgerieben werden. Den Kursverlauf sehe ich hier eher von weiteren Höhen und Tiefen geprägt, deshalb auch vielleicht ganz gut zum Traden geeignet.
Letztendlich dürfte der High Noon bei MYOG entweder die Zulassung oder eben eine Übernahme sein.

[Dionysius]

Habe meinen Einsatz rausgezogen und lasse jetzt den Gewinn, immerhin 50 %, mindestens 10 Monate liegen und warte ganz entspannt auf die Testergebnisse. Ich bin mir natürlich nicht sicher (sonst hätte ich nicht einen Teilverkauf vorgenommen), aber soweit ich das Bisherige verfolgt habe, sind die Aussichten auf positive Ergebnisse recht gut.
Schönen Gruss an alle sporadischen Leser und schönes Wochenende!
Dio

[bioperformer]

für die Geduldigen hat sich das Warten also doch gelohnt...

[Dionysius]

[posting]17.600.393 von bioperformer am 18.08.05 14:40:05[/posting]so ist es, für mich zumindest "zu einem Drittel" gelohnt

[bioperformer]

...dann also auf zu neuen Zielen..

[parakeet_luck]

GLÜCKWUNSCH!!

[[KERN]Codex]

Hmm und ich bin nicht dabei, weil ich es versäumt habe mich ausreichend damit zu beschäftigen

Glückwunsch!

[Teilnehmerin]

Wenn Sie einen Sprung macht - dann aber ganz gewaltig
wo wird die rally wohl noch hingehen ???

Onvista: 18.08.2005 16:52:32 (FIRST ALBANY)
Myogen "strong buy"
Rating-Update: Die Analysten von First Albany stufen die Aktie von Myogen (ISIN US62856E1047/ WKN 592817) unverändert mit "strong buy" ein. Das Kursziel sei von 28 auf 40 USD erhöht worden.

[Fruehrentner]

Und ich Depp seh Anfang August noch, wie die Aktie beginnt anzuziehen und steig nicht ein

[Fruehrentner]

Glückwunsch bioperformer!

Warst zwar in 2004 etwas früh dran, MYOGEN ausfindig zu machen, aber dafür startet sie jetzt ordentlich durch!

[Fruehrentner]

by the way,

wo kann man nachsehen, ob bei einer US-Aktie Insiderkäufe duch den CEO etc. erfolgen?

Hat jemand `nen link?

[bioperformer]

http://www.nasdaq.com/asp/Holdings.asp?mode=&kind=&timeframe…



Viel Spaß damit, Gruß Bio

[Fruehrentner]

nur um den thread nicht einschlafen zu lassen:

MYOGEN rennt weiter!

[Fruehrentner]

Bricht MYOGEN heute weiter nachhaltig nach oben aus?

bioperformer,

wie beurteilst du MYOGEN aktuell?


P.S. man beachte auch CELGENE!

[Dionysius]

und sie geht ganz gemütlich nach oben...

auf dass der thread nicht ganz in Vergessenheit gerät

Dio

[bioperformer]

mit den gestern veröffentlichten, unten angehängten News hat sich MYOG erneut ein deutliches Stück nach oben katapultiert.
Was die damit einhergegangene Performance des Wertes betrifft dürfte es gelungen sein bei der "Jahresendabrechnung" der erfolgreichsten Biotechs in 2005 ganz oben mit dabei zu sein...

bioperformer



NEWS von gestern:

UPDATE 3-Myogen vascular drug meets goal, shares surge
Mon Dec 12, 2005 09:03 PM ET
(Adds CEO comments)
By Julie Steenhuysen

CHICAGO, Dec 12 (Reuters) - Biotechnology company Myogen Inc. (MYOG.O: Quote, Profile, Research) said on Monday its experimental drug for a rare vascular disease met the primary goal in a late-stage study, sending shares up 40 percent.

The news weighed heavily on shares of rival drugmakers Actelion (ATLN.S: Quote, Profile, Research) of Switzerland and Houston-based Encysive Pharmaceuticals Inc.(ENCY.O: Quote, Profile, Research)

The Myogen drug, ambrisentan, helped improve exercise capacity and delay worsening of pulmonary arterial hypertension, or PAH, a blood vessel disorder of the lungs in which pressure in the pulmonary artery rises above normal levels.

Myogen, which is based in suburban Denver, said the drug also was generally well tolerated.

Myogen said ambrisentan had no apparent effect on the activity or dosage of warfarin-type anticoagulants commonly prescribed for patients with the condition.

Based on what he said were "extremely strong" results, CIBC World Markets analyst Bret Holley said he expects the drug ambrisentan to be approved in early 2007.

The news sent shares of Myogen up $7.90 to $27.14 on the Nasdaq, while shares of Actelion, maker of rival drug Tracleer, tumbled 19.2 percent in late trading on Monday in Switzerland.

Bill Freytag, Myogen`s chief executive, said results from a second pivotal-stage trial of ambrisentan are expected in the second quarter of next year.

If that trial is also successful, "it wouldn`t be unusual to be able to file with the FDA (U.S. Food and Drug Administration) within three or four months," the CEO said.

He said Myogen will seek a 6-month priority review by the FDA and will file at the same time for European regulatory approval of ambrisentan.

An Actelion spokeswoman said its flagship drug should continue to have a leadership role in treating PAH.

It was the second blow in as many weeks for Actelion, whose shares dived on Nov. 28 after a clinical trial found Tracleer failed to help patients with pulmonary fibrosis, a serious lung disease.

"People have been too optimistic on Tracleer, in our view, and sentiment is against them," said Karl Keegan, a biotech analyst with Canaccord Capital in London.

Shares of Encysive Pharmaceuticals, which is seeking regulatory approval in Europe and the United States for its PAH treatment, called Thelin, also took a hit on Myogen`s news, falling $3.20, or 28.62 percent, to $7.98 in Monday trade on Nasdaq.

Pfizer Inc. (PFE.N: Quote, Profile, Research) in June received FDA approval to sell Revatio, a drug that uses the active ingredient in erectile dysfunction treatment Viagra, as a treatment for PAH, which affects about 200,000 people worldwide.

Revatio and ambrisentan work by two different mechanisms of action and may eventually be used together, much as heart failure patients are now treated with a combination of therapies, Freytag said.

"At some point in the future, we will do that study," he said.

Patients with pulmonary arterial hypertension experience extreme shortness of breath as the heart struggles to pump against high pressure in the lungs, causing such patients to ultimately die of heart failure.

Myogen is also developing a treatment for resistant hypertension, darusentan, for which it is now talking with regulators about the design of a pivotal-stage trial. (Additional reporting by Deena Beasley in Los Angeles, Ben Hirschler in London and Saumyadeb Chakrabarty in Bangalore)

[[KERN]Codex]

Auf meiner Watchliste stehen sie jetzt an der Spitze mit +365%

[Fruehrentner]

Tja,

MYOGEN hatte ich auf der watchlist, aber dennoch vergessen, und das bei DEM Kursverlauf!!

Auf WO gilt offenbar, dass diejenigen Aktien die besten sind, die hier die geringsten Klickraten haben!

Leider gibts viel gepushe auf diesem Board


Heute gabs Zahlen:


06.03.2006 22:10:00 (BUSINESS WIRE

Myogen Reports 2005 Results

Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today reported 2005 full-year results. As of December 31, 2005, the Company had cash, cash equivalents and investments of $182.3 million. Net loss for the year ended December 31, 2005, was $63.0 million, or $1.68 per share, compared to a net loss of $57.7 million, or $2.00 per share last year.

Anzeige:
Bis 14% p.a. mit Tropenholz. Jetzt informieren!
■ Ökologisch sinnvolles Investment ■ schon ab 3.200,- EUR ■ Attraktive Rendite von bis zu 14%


"2005 was an incredibly exciting and rewarding year for Myogen and all of its constituents: patients, physicians, investors and employees," said J. William Freytag, President and Chief Executive Officer of Myogen. "We reported positive results for our two late-stage product candidates, ambrisentan and darusentan, as well as continued progress in our discovery research program and, with the support of the investment community, were able to secure additional funding to continue the advancement of these programs. 2006 looks to be another busy and potentially rewarding year with ambrisentan ARIES-1 data expected in April, initiation of our darusentan Phase 3 program and launch of commercial operations for Flolan expected in the second quarter and, hopefully, the submission of the ambrisentan NDA in the fourth quarter."



2005 Highlights



-- Positive top line results of darusentan Phase 2b resistant hypertension clinical trial



-- Positive top line results of ambrisentan ARIES-2 Phase 3 pulmonary arterial hypertension clinical trial



-- $125 million equity financing



Product Portfolio Update



Ambrisentan: Ambrisentan is a non-sulfonamide, propanoic-acid class, type-A selective endothelin receptor antagonist that is being evaluated as a once-daily oral therapy for patients with pulmonary arterial hypertension (PAH). Ambrisentan has been granted orphan drug designation for the treatment of PAH in both the United States and European Union.



ARIES-1 & -2



ARIES-1 & -2 are two pivotal Phase 3 trials evaluating ambrisentan in patients with PAH. Each trial was designed to enroll 186 patients. ARIES-1 enrolled 202 patients primarily from North America plus selected international sites, while ARIES-2 enrolled 192 patients primarily in Europe plus selected additional international sites. Positive top line results for ARIES-2 were reported in December 2005. Additional results of the trial will be presented at ATS 2006 -- San Diego, the annual International Conference of the American Thoracic Society to be held May 19-24, 2006, at the San Diego Convention Center in San Diego, California.

Patient enrollment in ARIES-1 was completed on November 30, 2005, and the last patient completed the 12-week trial on February 21, 2006. The Company expects to report top line results of the trial in April 2006. The primary efficacy endpoint of this trial is the change from baseline in the six-minute walk distance evaluated after 12 weeks of therapy compared to placebo. With a targeted sample size of 62 patients per arm, the trial has approximately 90% power to detect a placebo-corrected treatment effect of 35 meters for each dose group. A fixed-sequence approach for analysis, starting with the 10 mg dose and then proceeding to the 5 mg dose, will be used to control the Type I error for the two comparisons.

After the initial 12-week assessment period, all patients in the ARIES trials have the option to continue ambrisentan therapy in a long-term study. To date, more than 400 patients have been enrolled in this and other long-term studies. The incidence of confirmed serum aminotransferase test results greater than three times the upper limit of the normal range (3xULN) remains less than 1%.



AMB-222



In February 2006, the Company announced positive top line results of AMB-222, an open-label trial in which ambrisentan was administered to 36 PAH patients who had previously discontinued bosentan, sitaxsentan or both due to serum aminotransferase abnormalities. The primary endpoint of the trial was the incidence of serum aminotransferase concentrations greater than 3xULN during the 12 week evaluation period that resulted in discontinuation of drug treatment.

None of the 36 patients enrolled in the study had a recurrence of liver function abnormalities that resulted in discontinuation of ambrisentan during the initial 12-week evaluation period (the primary endpoint of the study). One patient had a transient serum aminotransferase test result greater than 3xULN at week 12 that resulted in dose reduction from 5 mg to 2.5 mg ambrisentan. This patient remains on ambrisentan therapy and has not had a recurrence of serum aminotransferases greater than 3xULN. Patients have continued to receive ambrisentan therapy for periods up to 10 months (mean exposure of 6 months) and no further occurrence of serum aminotransferase concentrations greater than 3xULN has been observed.



AMB-105



The Company recently completed a Phase 1 study examining the potential for drug-drug interactions between ambrisentan and sildenafil. The study results demonstrated that multiple doses of ambrisentan had no significant interaction with sildenafil. Similarly, multiple doses of sildenafil did not alter the pharmacokinetics of ambrisentan. Full results of AMB-105 will be submitted for presentation at a future scientific conference.



AMB-106



The Company recently completed a Phase 1 study examining the potential for drug-drug interactions between ambrisentan and warfarin. The study results demonstrated that multiple doses of ambrisentan had no significant effect on prothrombin time, international normalized ratio (INR) and/or the pharmacokinetics of warfarin. Full results of AMB-106 will be submitted for presentation at a future scientific conference.

Darusentan: Darusentan is a non-sulfonamide, propanoic-acid class, type-A selective endothelin receptor antagonist that is being evaluated as a once daily oral therapy for patients with resistant hypertension.



DAR-201



In August 2005, the Company announced positive top line results of a Phase 2b randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety and efficacy of darusentan in patients with resistant systolic hypertension. Enrollment of 115 patients was completed in April 2005. Patients underwent forced titration every two weeks through 10, 50, 100 and 150 mg of darusentan or placebo until the target dose of 300 mg once a day was achieved. The treatment period for the study was 10 weeks.

Results of the trial demonstrated that 300 mg of darusentan dosed once daily provided statistically significant, placebo-corrected reductions in systolic and diastolic blood pressure. Clinically meaningful reductions in systolic and diastolic blood pressure were also observed at earlier time points at lower doses. Trial results also demonstrated darusentan was generally well tolerated suggesting a favorable safety profile. There was no difference in the incidence of premature discontinuations in the darusentan arm compared to the placebo arm. Furthermore, there were no observed serum aminotransferase concentrations above two times the upper limit of the normal range. Additional results from the Phase 2b study will be presented at ACC.06, the 55th Annual Scientific Session of the American College of Cardiology, which will be held March 11-14, 2006, in Atlanta, Georgia.

Based on these results, the Company plans to conduct an international Phase 3 clinical program (DAR-311 and DAR-312) to further evaluate darusentan for the treatment of patients with resistant hypertension. The Company expects to initiate the Phase 3 program in the second quarter of 2006.



DAR-311



The primary objective of this Phase 3 randomized, double-blind, placebo-controlled parallel group trial is to determine if darusentan is effective in reducing systolic blood pressure in resistant hypertension patients currently treated with full doses of four or more antihypertensive medications, one of which is a diuretic. Patients are eligible for enrollment in this trial if they have a systolic blood pressure greater than or equal to 140 mmHg and no other compelling conditions. For patients with diabetes and chronic kidney disease, the blood pressure inclusion criterion is a systolic blood pressure greater than 130 mmHg. Approximately 352 patients will be randomized to one of three doses of darusentan (50, 100, or 300 mg qd) versus placebo in a ratio of 7:7:7:11. The treatment period for the trial is 14 weeks. The primary endpoint of the trial is change from baseline to week 14 in trough sitting systolic blood pressure as compared to placebo. Upon completion of the 14-week assessment period, patients will be eligible to enroll in a long-term safety study.



DAR-312



The primary objective of this Phase 3 randomized, double-blind, placebo-controlled trial is to determine if darusentan is effective in reducing systolic blood pressure in patients with resistant hypertension. Patients are eligible for enrollment in this trial if they have a systolic blood pressure greater than or equal to 140 mmHg despite treatment with full doses of three antihypertensive drugs, one of which is a diuretic, and no other compelling conditions. For patients with diabetes and chronic kidney disease, the blood pressure inclusion criterion is a systolic blood pressure greater than 130 mmHg. Approximately 770 patients will be randomized to darusentan, active control (guanfacine, an antihypertensive drug that acts as a central alpha agonist) or placebo, in a 3:3:1 ratio. The treatment period for the trial is 14 weeks. The efficacy analysis of the trial is change from baseline to week 14 in trough sitting systolic blood pressure compared to placebo and then compared to the active control. Upon completion of the 14-week assessment period, patients will be eligible to enroll in a long-term safety study.

Patients enrolled in the two long-term studies will be treated and followed for safety for at least six months with a mean exposure expected to be in excess of one year. The Company may undertake additional studies in this indication for commercial and regulatory support.



Drug Discovery Research: Myogen is continuing to move forward with its drug discovery program, which is the subject of a broad collaboration with Novartis. The program is focused on the discovery, development and commercialization of new therapeutics for the treatment of heart muscle disease.



Financial Highlights for 2005



In January 2006, the Company completed the sale of Myogen GmbH and the sub-license of the Perfan(R) I.V. rights, excluding the United States and Canada, for a total cash consideration of $6.1 million plus ongoing royalties. Accordingly, the assets, liabilities and results of operations pertaining to Myogen GmbH and Perfan(R) I.V. have been reclassified as "Discontinued Operations" in the attached summary financial statements. Sales of Perfan(R) I.V. for the year were $3.2 million versus $3.3 million in 2004.

Research and development contracts revenue from the Company`s research agreement with Novartis was $7.0 million for the year compared to $6.6 million in 2004.

Research and development expenses, excluding stock-based compensation expenses, decreased 3% to $52.6 million from $54.1 million for the years ended December 31, 2005 and 2004, respectively. The decrease in expenses for 2005 was primarily due to the discontinuation of the development of enoximone capsules.

Selling, general and administrative expenses, excluding stock-based compensation expenses, increased 57% to $13.1 million for 2005 from $8.4 million in 2004. The increase was primarily due to increased marketing costs associated with ambrisentan pre-launch activities, staffing and related recruiting costs and an increase in professional service costs.



2006 Milestones



Myogen is working towards several significant milestones in the coming year, including:



-- Reporting ARIES-1 top line results in April;



-- Initiating the darusentan Phase 3 clinical program during the second quarter;



-- Launching commercial operations for Flolan in the second quarter; and



-- Submitting the ambrisentan New Drug Application during the fourth quarter, should the ARIES-1 results support such a submission.



2006 Financial Guidance



The darusentan development program outlined above has only recently been finalized and the detailed costs and timelines are still under review and revision. Similarly, the partnership with GlaxoSmithKline announced earlier today will impact both our costs and potential revenues. Consequently, we are not providing detailed financial guidance at this time. However, we believe our cash, cash equivalents and investments, together with expected licensing proceeds, will be sufficient to fund operations until at least the end of 2007. Financial projections such as this one entail a high level of uncertainty due, among many factors, to the variability involved in predicting clinical trial initiation timelines, enrollment rates and results, product revenue and the potential for Myogen to enter into additional licensing or strategic collaborations.



Commercial Operations Management



With the successful partnering of ambrisentan, John Julian, Senior Vice President, Commercial Development, announced that he will be retiring effective the end of May 2006.

Robert Caspari, M.D., joins Myogen as Senior Vice President, Commercial Operations. Dr. Caspari has over 25 years` experience in the pharmaceutical, biotechnology and medical fields at Schering Plough, Boehringer Mannheim Corporation, Lederle Laboratories, Somatogen, Baxter International, Neorx Corporation and Novo Nordisk Pharmaceuticals, Inc. Dr. Caspari is trained as an internist and has devoted much of his career to launching and supporting pharmaceutical products. Most recently, Dr. Caspari was Vice President and General Manager of Novo Nordisk`s US Biopharmaceuticals Business Unit.

During the overlap of Mr. Julian and Dr. Caspari, Mr. Julian will serve as a senior advisor to the Company. Subsequent to the end of May, Mr. Julian will remain a consultant to the Company, providing strategic advice in the field of commercial development. The Company wishes to thank John for his six years of devoted service to Myogen and for all the contributions he has made.



Conference Call



J. William Freytag, President and CEO, and other members of Myogen`s senior management will provide a company update and discuss results via webcast and conference call on Monday, March 6, 2006, at 4:30 p.m. Eastern. To access the live webcast, please log on to the company`s website at www.myogen.com and go to the Investor Relations section. Alternatively, callers may participate in the conference call by dialing 800-218-0204 (domestic) or 303-262-2068 (international). Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Friday, March 31, 2006. Callers can access the replay by dialing 800-405-2236 (domestic) or 303-590-3000 (international). The passcode is 11052811#.



About Myogen



Myogen has two product candidates in late-stage clinical development: ambrisentan for the treatment of patients with pulmonary arterial hypertension (PAH) and darusentan for the treatment of patients with resistant hypertension. The Company, in collaboration with Novartis, also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders. Please visit the company`s website at www.myogen.com.

[Fruehrentner]

Ebenfalls von heute abend folgende Meldung:

Glaxo vereinbart Zusammenarbeit mit Myogen - Rechte an Ambrisentan
NEW YORK (dpa-AFX) - Der britische Pharmakonzern Glaxo Smith Kline hat mit der amerikanischen Myogen eine Zusammenarbeit bei der Behandlung von Bluthochdruck in der Lunge vereinbart. Wie beide Unternehmen am Montagabend mitteilten, wird Glaxo die exklusiven Rechte des Medikamentenkandidaten Ambrisentan außerhalb der USA erhalten. Das Mittel befindet sich in der Phase III und soll den Planungen nach in diesem Jahr zur Zulassung in Europa und den USA eingereicht werden.

Zudem soll Myogen die Vermarktung von Glaxo`s Medikament Flolan in den USA übernehmen. Das Mittel wird ebenfalls gegen die so genannte pulmonale arterielle Hypertonie (PAH) eingesetzt.

Myogen erhält für die Weitergabe der Ambrisentan-Rechte eine Vorauszahlung von 20 Millionen Dollar sowie bei Erreichen so genannter Meilensteine erfolgsabhängige Zahlungen von bis zu 80 Millionen Dollar. Zudem wird Myogen am Umsatz beteiligt./she
Quelle: dpa-AFX

[Bananenflanke]

Seit Vereinbarung mit Glaxo über die Weitergabe der Ambrisentan-Rechte
ausserhalb der USA läuft der Kurs von Myogen seitwärts so um die 35 $.
Es hat wohl so manchem Investierten nicht geschmeckt, aber ich sehe
dies eher positiv. Immerhin ist Galxo einer der größten Pharmakonzerne
und erfahren in der Vermarktung von Medikamenten, wovon Myogen nur profitieren kann.
Zudem ist es gut einen starken Partner zu haben.

[bioperformer]

>>>Interessante News heute bei MYOG...



Press Release Source: Myogen, Inc.


Ambrisentan Phase 3 ARIES-2 PAH Data Presented At ATS 2006 -- San Diego
Wednesday May 24, 6:30 am ET
Significant Improvement in Six-Minute Walk Distance and in Time to Clinical Worsening with No Observed Liver Function Abnormalities


SAN DIEGO--(BUSINESS WIRE)--May 24, 2006--Myogen, Inc. (Nasdaq: MYOG - News), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced that a scientific presentation describing the effects of ambrisentan in patients with pulmonary arterial hypertension (PAH) was given at ATS 2006 -- San Diego, the annual International Conference of the American Thoracic Society.
ADVERTISEMENT


The oral presentation highlighted efficacy and safety results from ARIES-2, the Phase 3 trial of ambrisentan in 192 patients with PAH. The data demonstrate that ambrisentan improved exercise capacity, delayed clinical worsening and improved symptoms in patients with PAH. Ambrisentan was well tolerated and was not associated with any clinically significant serum aminotransferase abnormalities or drug-drug interactions with warfarin-type anticoagulants. Myogen reported the top line results of the trial in December 2005.

Horst Olschewski, M.D., presented "Ambrisentan Improves Exercise Capacity and Time to Clinical Worsening in Patients with Pulmonary Arterial Hypertension: Results of the ARIES-2 Study." Dr. Olschewski is Professor of Medicine, Division of Pulmonology, Medical University Graz, Austria and a principal investigator for ARIES-2.

Patients in this trial were primarily women (75%). The etiology of the PAH was 65% idiopathic and 35% associated with other causes. Patients entered the trial in World Health Organization (WHO) Functional Class I/II (47%) and Class III/IV (53%). The patients were enrolled from Western Europe/Israel (52%), Eastern Europe (24%) and South America (24%). Mean six-minute walk distance (6MWD) at baseline was 348 meters +/- 84 meters.

The primary efficacy endpoint of the ARIES-2 trial was the placebo-corrected mean change in 6MWD at week 12 compared to baseline. Results of the trial demonstrated that with once-daily dosing, 5 mg of ambrisentan improved the placebo-corrected mean 6MWD by 59.4 meters (p = 0.0002) and 2.5 mg of ambrisentan improved the placebo-corrected mean 6MWD by 32.3 meters (p = 0.0219). For the placebo group, the mean 6MWD at week 12 decreased from baseline by 10.1 meters.

Improvements in time to clinical worsening compared to placebo were observed for both the 5 mg dose group (p=0.0076) and the 2.5 mg dose group (p=0.0048). Improvements in Borg dyspnea index compared to placebo were observed for both the 5 mg dose group (p = 0.0384) and the 2.5 mg dose group (p=0.0367). Improvements in SF-36 Health Survey® compared to placebo were observed for both the 5 mg dose group (p=0.040) and the 2.5 mg dose group (p=0.005). The pre-specified analysis of WHO functional class did not reach statistical significance; however, deterioration of at least one class was observed in 18% of placebo patients, compared to 5% of patients in the 2.5 mg ambrisentan dose group and 3% of patients in the 5 mg ambrisentan dose group.

The trial safety results demonstrated ambrisentan was well tolerated. The most frequent adverse event was headache, which occurred in 12.7% of patients in the 5 mg dose group and 7.8% in the 2.5 mg dose group, compared to 6.2% in the placebo group. There were four deaths in the placebo arm compared to two deaths (unrelated to drug) in the 2.5 mg ambrisentan dose group and none in the 5 mg ambrisentan dose group. Ambrisentan had no apparent effect on the activity or dosage of warfarin-type anticoagulants commonly prescribed for patients with PAH.

No patients treated with ambrisentan developed serum aminotransferase concentrations greater than three-times the upper limit of the normal range (3xULN), compared to one patient (1.5%) in the placebo group. As of May 2006, patients in the long-term follow-up study have a maximum drug exposure of 2.4 years and a mean drug exposure of one year. During this long-term treatment, the incidence of serum aminotransferase concentrations greater than 3xULN was less than 2% (0.6% confirmed upon re-test).

About Myogen

Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. Myogen currently has two product candidates in late-stage clinical development: ambrisentan for the treatment of patients with pulmonary arterial hypertension and darusentan for the treatment of patients with resistant hypertension. Myogen and GlaxoSmithKline have entered into a global PAH collaboration in which Myogen has distribution and marketing rights to GlaxoSmithKline's Flolan (epoprostenol sodium) in the United States and GlaxoSmithKline has sublicensed ambrisentan from Myogen for all territories outside of the United States, where Myogen retains exclusive rights. Myogen also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders. Please visit Myogen's website at www.myogen.com.

Safe Harbor Statement

This press release contains forward-looking statements that involve significant risks and uncertainties, including summary statements relating to the results of the Company's ARIES-2 clinical trial. Actual results could differ materially from those projected and the Company cautions investors not to place undue reliance on the forward-looking statements contained in this release.

Results from clinical trials, including the Company's ARIES-2 trial, are not necessarily predictive of future clinical results. Top line results may not be confirmed upon full analysis of the detailed results of a trial and additional information relating to the safety, efficacy or tolerability of the Company's product candidates, including ambrisentan, may be discovered upon further analysis of trial data and upon review and analysis of additional trial data, including data from the Company's ARIES-1 clinical trial and ARIES long-term study. If the Company's product candidates do not meet safety or efficacy endpoints in clinical evaluations, they will not receive regulatory approval and the Company will not be able to market them. Even if the Company's product candidates meet safety and efficacy endpoints, regulatory authorities may not approve them, the Company may not be able to successfully market them, or the Company may face post-approval problems that require the withdrawal of its product from the market. The Company's results may be affected by its effectiveness at managing its financial resources, its ability to successfully develop and market its product candidates, its ability to obtain and enforce patent protection for its products, competition from other biotechnology and pharmaceutical companies, difficulties or delays in manufacturing its products, and regulatory developments involving current and future products. Delays in initiating or conducting clinical trials, whether caused by competition, adverse events, patient enrollment rates, regulatory issues or other factors, could adversely affect the Company's financial position and prospects. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue one or more of its drug development or discovery research programs. Myogen may not ever have any products that generate significant revenue.

Additional risks and uncertainties relating to the Company and its business can be found in the "Risk Factors" section of Myogen's Form 10-K for the year ended December 31, 2005 and Myogen's reports on Form 10-Q and Form 8-K. It is Myogen's policy to only update or reconfirm its public guidance by issuing a press release or filing a periodic or current report with the Securities and Exchange Commission. All information in this press release is as of May 24, 2006. Myogen undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in the Company's expectations.



Contact:
Myogen, Inc.
Director, Investor Relations
Derek K. Cole, 303-464-3986
[e-mail]

[Fruehrentner]

Ob Myogen jetzt das ATH angreift?

Schade, dass diese Aktie hier praktisch nicht diskutiert wird.

[bioperformer]

Antwort auf Beitrag Nr.: 23.576.731 von Fruehrentner am 23.08.06 13:37:50

....im herbst wird sicher noch eine Biotech-Rallye kommen - da wird MYOG vorraussichtlich deftig von profitieren können, da sie quasi in keinem größeren US-Biotechfond fehlen darf.

Die bislang erzielte Performance zwingt die Fondsmanager förmlich dazu ihre Depots mit MYOG zu bereichern...

[Fruehrentner]

Antwort auf Beitrag Nr.: 23.584.839 von bioperformer am 23.08.06 21:39:25

Myogen zieht jetzt schon kräftig an!

Steigen die Fonds schon ein?

[Fruehrentner]

Antwort auf Beitrag Nr.: 23.682.188 von Fruehrentner am 30.08.06 12:55:23

Und der Kurs zieht weiter an!

[Fruehrentner]

02.10.2006 13:32:09

US-Pharmaunternehmen Gilead übernimmt Myogen für 2,5 Milliarden US-Dollar

FOSTER CITY (dpa-AFX) - Das US-Pharmaunternehmen Gilead will den Wettbewerber Myogen für 2,5 Milliarden US-Dollar übernehmen. Beide Unternehmen hätten eine entsprechende Vereinbarung unterzeichnet, teilte Gilead am Montag in Foster City mit. Gilead biete 52,50 US-Dollar pro Myogen-Aktie. Die Transaktion werde das Gilead-Ergebnis zunächst belasten, ab 2010 aber zu einem Anstieg des Gewinns führen./FX/fj/sbi

Quelle:dpa-AFX


Aktie +49 %!
Und ich Depp hab sie seit Monaten nur auf der watchlist!

[Fruehrentner]

02.10.2006 14:38:00

Gilead Sciences will Myogen übernehmen


Foster City (aktiencheck.de AG) - Das Biopharma-Unternehmen Gilead Sciences Inc. (ISIN US3755581036 / WKN 885823 ) und die Myogen Inc. (ISIN US62856E1047 / WKN 592817 ) haben eine definitive Vereinbarung über die von Gilead geplante Akquisition von Myogen unterzeichnet.

Unternehmensangaben vom Montag zufolge ist die Transaktion als zweiphasige Akquisition strukturiert, welche aus einem Cash-Übernahmeangebot für alle der ausstehenden Myogen-Stammaktion zum Preis von 52,50 Dollar je Aktie besteht, gefolgt von einer Cash-Fusion, bei der Gilead alle verbleibenden ausstehenden Myogen-Stammaktion zum Preis von 52,50 Dollar je Aktie erwirbt. Nach Abschluss des zweiten Teils der Fusion wird Myogen zu einer 100-prozentigen Tochtergesellschaft von Gilead.

Der Transaktionswert wird auf annähernd 2,5 Mrd. Dollar beziffert. Die Transaktion wird sich voraussichtlich mindernd auf das Einkommen von Gilead für 2007 und 2008 auswirken, neutral für 2009 und steigernd für 2010 und darüber hinaus.

Der führende Produktkandidat von Myogen, Ambrisentan, für die potenzielle Therapie von pulmonaler arterieller Hypertonie (PAH) ist ein oral verfügbarer Endothelin-Rezeptorantagonist. Beide Unternehmen sind der Überzeugung, dass die in zwei abgeschlossenen zentralen Studien der Phase III erhaltenen Daten einen Zulassungsantrag unterstützen würden. Myogen beabsichtigt, möglicherweise bereits im vierten Quartal 2006 einen Zulassungsantrag bei der US Food and Drug Administration einzureichen.

Das Board of Directors von Myogen hat sich einstimmig für die Empfehlung des Übernahmeangebots und der Fusion an seine Aktionäre ausgesprochen. Gilead und Myogen gehen davon aus, dass das Übernahmeangebot vor Ende 2006 schließen wird.

Am Freitag stiegen die Aktien an der Nasdaq um 0,10 Prozent und schlossen bei 68,70 Dollar. (02.10.2006/ac/n/a)

Quelle: Finanzen.net / Aktiencheck.de AG

[bioperformer]

...so, hat sich doch gelohnt wenn man dabeigeblieben ist und schön das ganze von der medizinischen Seite betrachtet und mitverfolgt hat.

[Fruehrentner]

Der Vollständigkeit wegen:

18.11.2006 18:27:00

Gilead Sciences vollzieht Myogen-Übernahme

Gilead Sciences, Inc. (Nasdaq:GILD) hat heute die erfolgreiche Übernahme von Myogen, Inc. (Nasdaq:MYOG) bekannt gegeben.

Die Fusion des hundertprozentigen Gilead-Tochterunternehmens mit Myogen wurde am 17. November 2006 wirksam. Am 13. November, eine Minute nach 23.59 Uhr New Yorker Zeit, hatte Gilead seine Cash-Offerte von 52,50 USD für jede im Umlauf befindliche Myogen-Stammaktie erfolgreich abgeschlossen. Mit der Fusion wurden die ausstehenden Stammaktien von Myogen in einen unverzinsten Bargeldanspruch in Höhe des Übernahmeangebots von 52,50 USD umgewandelt. Voraussetzung für diese Regelung ist, dass sich die Wertpapiere weder im Besitz von Gilead, Myogen oder derer Tochterunternehmen, noch von solchen Aktionären befinden, die von ihrem Barabfindungsrecht Gebrauch machen. Myogen-Aktionäre, deren Aktien im Rahmen des Übernahmeangebots nicht ordnungsgemäß eingereicht und somit zurückgewiesen wurden, erhalten in Kürze eine Fusionsmitteilung und ein Begleitschreiben mit Hinweisen zur Auszahlung der Fusionsvergütung. Zur Abkürzung des Fusionsverfahrens hat Gilead eine im Fusionsvertrag vorgesehene Aufstockungsoption eingesetzt, die einem Gilead-Tochterunternehmen den Ankauf einer begrenzten Anzahl weiterer Myogen-Stammaktien zum Stückpreis von 52,50 US-Dollar direkt von Myogen garantiert (d.h. zum Preis des Übernahmeangebots).

Wie zuvor mitgeteilt wird Gilead während der Konferenzschaltung am 31. Januar 2007, im Rahmen der Veröffentlichung der Q4-Geschäftsdaten sowie der Jahresbilanz für 2006, Informationen über die Auswirkungen der Myogen-Übernahme auf die Betriebskosten des Bilanzjahres 2007 zur Verfügung stellen.

Über Gilead Sciences

Gilead Sciences ist eine biopharmazeutische Gesellschaft, die innovative Therapeutika für Anwendungsbereiche mit bisher nicht gedecktem medizinischem Bedarf erforscht, entwickelt und vermarktet. Das Ziel des Unternehmens besteht in der weltweiten Verbesserung der Versorgung von Patienten mit lebensbedrohenden Erkrankungen. Gilead hat seine Unternehmenszentrale im kalifornischen Foster City und Niederlassungen in Nordamerika, Europa und Australien.

Nähere Informationen über Gilead Sciences erhalten Sie auf der Website des Unternehmens unter www.gilead.com oder telefonisch bei der Gilead-Abteilung Public Affairs unter 1-800-GILEAD-5 oder 1-650-574-3000.


Quelle:BUSINESS WIRE